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Abstract 
EXTRACELLULAR GLUTAMATE, GLUTAMINE, AND GABA IN THE 
HIPPOCAMPUS AND CORTEX OF REFRACTORY EPILEPSY PATIENTS. 
Jonathan C. Romanyshyn and Idil Cavus MD, PhD. Departments of Psychiatry and 
Neurosurgery, Yale University School of Medicine, New Haven, CT. 
 
Antiepileptic drug (AED) resistance affects one third of patients with epilepsy 
and is associated with significant disability. Brain microdialysis studies on the 
epileptogenic hippocampus of patients with medication refractory epilepsy have 
identified elevations in extracellular glutamate, the primary brain excitatory 
neurotransmitter, both acutely during seizures and chronically during the interictal 
periods.  Whether extracellular glutamate, along with the metabolites glutamine and the 
inhibitory neurotransmitter GABA (gamma-aminobutyric acid), are elevated in other 
cortical regions is unknown. In addition, the effect of the administration of AEDs on the 
extracellular levels of these neurochemicals in patients with medication-refractory 
epilepsy is also unknown. 
Microdialysis samples were obtained from probes coupled to the EEG depth 
electrodes and implanted in the cortex and hippocampus of 81 awake patients with 
medication-refractory epilepsy undergoing intracranial electroencephalographic (EEG) 
monitoring.  Probes were classified according to location and seizure activity into cortical 
or hippocampal non-epileptic, epileptogenic, propagated, non-localized or lesion sites. 
Samples were collected during the interictal period, in all subjects on their full AED dose 
during the first couple of days of their hospitalization, and then again (in a subset of 38 
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patients) after their AEDs were tapered.  The samples were analyzed with high 
performance liquid chromatography (HPLC) for glutamate, glutamine and GABA levels. 
Data were log-transformed and compared by ANOVA or multiple t-tests with a 
Bonferroni correction, where appropriate. 
In the cortex, glutamate was significantly higher in epileptogenic (mean ± 
SEM, 17.3 ± 5.1 µM), propagated (25.8 ± 4.0 µM), non-localized (43.9 ± 9.9 µM), and 
lesion (46.9 ± 9.0 µM) sites compared to non-epileptic cortex (2.6 ± 0.3 µM). In the 
hippocampus, glutamate was significantly higher in the epileptogenic (10.3 ± 1.9 µM) 
and propagated sites (33.0 ± 13.8 µM) than non-epileptic sites (2.8 ± 0.5 µM). Glutamine 
was not significantly different between sites in both the cortex and hippocampus. In the 
cortex, GABA was significantly elevated in propagated (1503 ± 273 nM) and lesion (827 
± 183 nM) sites compared to non-epileptic sites (265 ± 62 nM). In the hippocampus, 
GABA was elevated in the propagated (1079 ± 395 nM) compared to non-epileptic sites 
(391 ± 169 nM). 
There were no significant differences in glutamate, glutamine, or GABA 
between the hippocampus and cortex within non-epileptic, epileptogenic, or propagated 
sites, which enabled cortical and hippocampal probes to be combined. Glutamate was 
now found to be significantly elevated in propagated compared to non-epileptic sites (p = 
0.0001). GABA was significantly elevated in epileptogenic compared to non-epileptic 
sites (p = 0.011) and in propagated compared to epileptogenic sites (p = 0.028). 
After AED taper, there were no significant changes in glutamate in any site, 
although it decreased non-significantly in non-localized sites (p = 0.090). Glutamine 
decreased significantly in lesion sites (p = 0.0095). GABA declined significantly in non-
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localized sites (p = 0.014). When all sites were examined together, there were overall 
significant decreases in glutamine (p = 0.0011) and GABA (p < 0.0001). 
            In conclusion, elevations in glutamate and GABA extend beyond epileptogenic 
sites in patients with refractory epilepsy. Levels of glutamate, glutamine, and GABA 
were comparable between the hippocampus and cortex. AEDs may increase extracellular 
levels of glutamine and GABA but are inefficient in reducing glutamate to normal levels 
in these patients, which may relate to AED resistance. 
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Background 
Introduction 
Epilepsy, a disorder characterized by repeated unprovoked seizures, affects 1-3% 
of the population (1). Epilepsy is broadly classified as localization-related or generalized, 
depending on whether it originates in one hemisphere or involves the cortex bilaterally, 
respectively. Epilepsy can be further characterized as idiopathic, which suggests a genetic 
basis and is not associated with a structural abnormality; symptomatic, in which a 
structural cause is identified; and cryptogenic, in which a structural cause is suspected but 
is not identifiable with current modalities. The initial treatment for epilepsy consists of 
administration of antiepileptic drugs (AEDs), which are thought to mitigate epileptic 
activity by either reducing neuronal excitation or increasing inhibitory tone. Failure to 
respond to the first AED heralds poor seizure control, since the probability of response to 
successive AEDs follows the law of diminishing returns: 47% of patients will respond to 
their first AED, 13% will respond to the second, and 4% respond to the third or more (2). 
Despite the development of new AEDs, 25-30% of patients remain refractory to 
medications (2). Surgery is a consideration for a subset of patients with intractable 
localization-related epilepsy, and seizure freedom is achieved only in two-thirds of mesial 
temporal and in one half of neocortical resections (3). For the remaining patients, no cure 
is available. Therefore, it is necessary to gain a better understanding of drug-resistant 
epilepsy to guide future therapies. 
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Medication-Resistant Epilepsy: 
Drug-resistant epilepsy is a significant public health concern. It is associated with 
a mortality rate five times greater than the general population (4) and with psychiatric 
comorbidities, social disability, and a reduced quality of life (5). The type of epilepsy 
predicts drug-responsiveness. Greater seizure control is achieved in patients with 
idiopathic generalized epilepsy (86%) compared to patients with generalized 
symptomatic or cryptogenic epilepsy (26%), symptomatic partial epilepsy (35%), and 
cryptogenic partial epilepsy (45%) (6).  The presence of identifiable lesions decreases 
drug-responsiveness dramatically to 24% in cerebral dysgenesis, 11% in hippocampal 
sclerosis alone, and 3% in dual pathology (the presence of hippocampal sclerosis in 
conjunction with another lesion). Although most drug resistance becomes apparent soon 
after a medication is initiated, some patients exhibit deterioration years after a successful 
drug response (7). Other poor prognostic indicators include early age of onset, 
developmental delay, multiple seizures prior to treatment, failure of early treatment to 
control seizures, complex febrile seizures, status epilepticus, and generalized 
electroencephalographic (EEG) activity (2, 8). 
Molecular theories on medication resistance fall into two main categories: 1) 
reduced sensitivity of the target to the medication and 2) poor concentration of 
medication at the target site (9). Alterations in sodium channels and GABA receptors 
induced by epileptic changes or genetic mutations underlying epilepsy may affect drug 
binding and efficacy. For example the changes in GABAA receptor configuration in 
epileptic rat hippocampi may mediate phenobarbital resistance (10, 11), and alterations in 
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sodium channel properties may underlie carbamazepine resistance (12). Although its role 
in resistance is uncertain, the molecular target of levetiracetam is decreased in patients 
with hippocampal sclerosis and in chronically epileptic rats (13). The transporter 
hypothesis, which is better studied due to previous work on cancer chemotherapy 
resistance, posits that the expression of efflux transporters, such as p-glycoprotein (P-gp) 
and multi-drug resistance proteins (MRPs), actively prevent drug accumulation in the 
brain parenchyma. The overexpression of drug transporters in lesions and other epileptic 
foci may explain why symptomatic focal epilepsies are more drug-resistant than 
idiopathic epilepsies, in which the anomalies are more evenly distributed (14). 
Localization-Related Epilepsy: 
The term localization-related epilepsy suggests that a discrete site of seizure onset 
is identifiable, either through imaging or electrographic study. These epilepsies can be 
broadly divided into mesial temporal lobe (MTL), lesional, and nonlesional cortical 
onsets. The MTL is the most common site of localization-related epilepsy and is 
associated with mesial temporal sclerosis (MTS) in 70% of patients (15). MTS is 
characterized by hippocampal cell loss, atrophy, and gliosis (15). Causes of lesional 
epilepsy include tumors, vascular malformations, infarct- or trauma-related 
encephalomalacia, and developmental anomalies (16). Focal developmental 
malformations are due to abnormal neurogenesis, neuronal migration, or cortical 
organization and include focal cortical dysplasia, heterotopia, polymicrogyria, and 
schizencephaly (17). In addition to their pathological correlates, MTS and lesional 
epilepsy can often be identified preoperatively through MRI (18). Nonlesional cortical 
epilepsy, also referred to as cryptogenic or non-substrate-directed partial epilepsy, is not 
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anatomically distinct from surrounding brain on MRI but may be identified by abnormal 
physiology detected on nuclear medicine studies, such as PET or SPECT (16). 
Histologically, nonlesional epilepsy may demonstrate gliosis, focal cell loss, and 
developmental anomalies, but sometimes no abnormality can be perceived (19).  
Theories of Epileptogenesis: Focus or Network 
The extent of brain tissue necessary for seizure generation is a matter of 
controversy. Whether epileptogenesis is a product of a discrete "focus", a larger "irritative 
zone", or a distributed property of a wider network has been disputed (20). The theory 
proposed by Penfield and Jasper in the 1950s that the ictal onset zone alone is necessary 
for epileptogenesis (21) continues to guide to the extent of surgical resection. In the 
1990s Tailarch and Bancaud proposed that epileptogenesis involves the area of 
immediate seizure propagation in addition to the ictal onset zone (22). More recently, the 
late Susan Spencer proposed that epileptogenesis is distributed equally through a wider 
network rather than being localized to one discrete area, which implies that disruption of 
the network at any point can abolish epileptogenesis (23). Of these epileptogenic 
networks, the best characterized is the medial temporal network, which involves 
connections between the hippocampus, amygdala, temporal pole, temporal neocortex, 
and orbitofrontal cortex (24). Others include the medial occipital/lateral temporal and 
superior parietal/medial frontal networks (23). Knowledge of the necessary constituents 
of epileptogenesis has treatment implications. For example, the presence of seizure 
termination outside of the onset site predicts a poor outcome following resection of the 
epileptogenic focus alone, which has been proposed to be due to globally reduced 
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inhibitory tone (25). Consequently, a better understanding of the elements of seizure 
propagation is needed. 
Identification of Seizure Focus: Role of Medication Withdrawal 
Before resective surgery can be considered for patients with medication-refractory 
epilepsy, inpatient continuous audio-visual EEG recording (AV-EEG), with either scalp 
or intracranial electrodes (icEEG) depending on the complexity of localization, is 
employed to identify the site of seizure onset. In this procedure, patients are admitted on 
their full outpatient AED dose, and medications are then gradually withdrawn to increase 
the habitual seizure frequency in order to shorten the recording period. In one study on 
patients with TLE undergoing medication taper during AV-EEG monitoring, the first 
habitual seizure was recorded after a mean of 4.4 days, and 7.4 days were required to 
record three habitual seizures (26). In another study examining AED taper, the first CPS 
was recorded after a mean of 3.2 days, and the mean monitoring period lasted 6.4 days 
(27). 
The increase in seizure frequency is most prominent immediately after drug 
withdrawal and depends on the half-life of the AED (28). The increase in seizure 
frequency does not require a significant drop in AED levels, as the first CPS is often 
recorded when drug levels in the blood are sub-therapeutic rather than minimal (27). 
Since AED administration leads to a greater reduction in seizure frequency in patients 
with temporal lobe epilepsy (TLE) than extra-temporal epilepsy, TLE patients often 
requires a greater AED dose reduction to obtain an adequate number of seizures for 
localization during monitoring (26). 
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For most medications, including commonly-used carbamazepine and valproate, 
medication taper enhances seizure propagation but does not change the characteristic 
patterns of seizure onset (29), which is an important consideration when the results of the 
electrographic study guide the extent of surgical resection. In contrast withdrawal of 
barbiturates and benzodiazepines can cause atypical seizures that are falsely localizing 
(30), so doses of these two classes of medications are left unchanged during taper 
protocols. However, in patients with previously undiagnosed multifocal epilepsy, the 
taper of non-benzodiazepine/barbiturate AED may also appear to alter seizure onset 
patterns, because it unmasks atypical seizures arising from other onset foci (30). Clinical 
medication taper effects vary with each medication, which may influence the design of a 
taper protocol. For example, discontinuation of carbamazepine (31) and its metabolite 
oxcarbazepine (32) dramatically increase seizure frequency, including generalized tonic-
clonic seizures, acute due to a rebound phenomenon, while tapering of phenytoin and 
valproate do not exhibit this marked effect (32). 
While AED-taper-related changes have not been previously been studied by 
microdialysis in humans, electrographic studies at our center have identified a decrease in 
interictal spike frequency and interictal EEG Teager energy after medication withdrawal. 
The reduction in interictal spike frequency is a global phenomenon, not restricted to 
epileptogenic areas, related to drug taper seen in both hippocampal- and neocortical-onset 
epilepsies that may reflect a reduction in inhibitory tone (33). In contrast to spikes, high 
frequency oscillations do increase after medication taper and appear related to seizure 
susceptibility (34). Teager energy, which measures high-frequency energy and is 
positively correlated to increased extracellular glutamate (35), has been found to decrease 
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both globally and within epileptogenic sites during AED taper, suggesting that AEDs 
may have anti-seizure effects unrelated to reductions in excitation and overall signal 
energy (36). 
In Vivo Microdialysis   
Technique: 
 Microdialysis was first introduced in the 1970s for neurochemical research in 
animals. This innovation enabled in vivo studies of the extracellular concentrations of 
ions, drugs, and neurotransmitters in freely-moving animals, in contrast to previous 
analytic methods that required animal sacrifice for tissue extraction (37, 38). In the 1990s 
microdialysis was extended to investigations in humans and has enabled real-time 
sampling of the extracellular milieu in trauma, stroke, tumor, and epilepsy. In brief, a 
microdialysis probe tipped with a semi-permeable membrane (usually 5-20 kDa) is 
implanted in the brain region of interest. It is then infused with a solution isotonic to the 
surrounding extracellular fluid (ECF), enabling solutes to diffuse into the fluid according 
to their concentration gradients, and the dialysate is collected at regular time intervals and 
analyzed by high-performance liquid chromatography (HPLC), mass spectroscopy, or 
enzymatic reaction for the molecule of interest. At a constant infusion rate, the 
concentration of a solute within the dialysate is proportional to its concentration in the 
brain ECF, a ratio termed the fractional recovery. Properties of the diffusing molecule, 
blood brain barrier integrity, inflammation surrounding the probe, temperature, flow rate, 
and attributes of the probe can influence the fractional recovery, which can be increased 
by decreasing flow rates and lengthening the dialysis membranes (37, 39). The true 
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concentration of the substance in the brain ECF can be extrapolated from the 
concentration in the dialysate using either the zero-flow (40) or the no-net-flux (41, 42) 
methods. Another advantage of microdialysis is its ability to follow concentrations in 
real-time; the temporal resolution of microdialysis can be enhanced by increasing the 
perfusate flow rate and shortening the collection intervals.  
Microdialysis Studies in Epilepsy Patients:  
In human epilepsy studies the microdialysis catheter can be coupled to a depth 
electrode and implanted into hippocampal or cortical areas of interest, allowing 
correlation of the local neurochemical changes with the electrical activity. Because of the 
invasive nature of this technique, all of the human microdialysis data have been obtained 
in patients with medication-refractory epilepsy who are undergoing other neurosurgical 
procedures. In the first reported human microdialysis study, Carlson et al. 
intraoperatively sampled the epileptogenic frontal cortex of an anesthetized patient 
undergoing resective surgery and noted elevations in extracellular glutamate, aspartate, 
glycine, and serine during a period of status epilepticus partialis (43). Ronne-Engstrom et 
al. performed intraoperative microdialysis on seven anesthetized patients and observed 
similar neurochemical changes after electrically stimulating the epileptogenic site (44). 
Thomas et al. found that extracellular levels of glutamate, GABA, and aspartate 
measured intraoperatively in the anterior hippocampus of patients with MTLE correlated 
with electrical activity (45) but were unable to appreciate differences between the 
hippocampus and adjacent lateral temporal lobe (46). 
During and Spencer, the first investigators to perform microdialysis in awake 
patients, measured the extracellular concentrations of glutamate and GABA in epileptic 
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and non-epileptic hippocampi during spontaneous seizures (47). They observed a rise in 
glutamate levels in the epileptic hippocampus immediately preceding the seizure, which 
was followed by a dramatic increase during the seizure and continued post-ictal 
elevation. During and Spencer also measured an increase in GABA during the seizure 
that, interestingly, was even greater in the contralateral non-epileptic than ipsilateral 
epileptic hippocampus. Wilson et al. found that glutamate and GABA in the hippocampi 
of awake patients with MTLE rose similarly with seizures (48); although, the rise in 
glutamate was not as great as that reported by During and Spencer, and they did not 
discern any differences between the epileptogenic and contralateral hippocampi. 
Cavus and colleagues (35, 49-52) have focused on the basal levels of extracellular 
glutamate, glutamine and GABA during the interictal period, six hours away from seizure 
activity, of awake medication-resistant epilepsy patients undergoing intracranial EEG 
evaluation. They have found that the epileptogenic hippocampus has significantly higher 
basal glutamate levels than the non-epileptic hippocampus and that this is associated with 
a low glutamine/glutamate ratio and impaired glucose metabolism (49). Furthermore, the 
elevated glutamate in the hippocampi correlated with the degree of hippocampal atrophy 
(50), decreased hippocampal neuronal count (52) and was associated with poor cognitive 
functioning (53).  
Elevated hippocampal basal glutamate was also found to be correlated with EEG 
Teager energy, a measure of high-frequency EEG power, and to be associated with 
hyperexcitability measured in ex vivo tissue preparations (35). In contrast, the results 
related to the cortical glutamate were more mixed. In the initial study, with limited 
cortical sampling, glutamate in the epileptogenic cortex was not significantly elevated 
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compared to the non-epileptic cortex and did not have the same metabolic associations as 
in the epileptogenic hippocampus (49). Later preliminary data collected from a similar 
patient population, suggested that glutamate is elevated in regions of seizure propagation 
as well as in onset sites (35).. More limited information has been obtained regarding the 
basal levels of the inhibitory neurotransmitter GABA. In conjunction with magnetic 
resonance spectroscopy (MRS), Pan, Cavus, et al. have found that while in the 
epileptogenic hippocampi higher basal GABA is correlated with impaired mitochondrial 
function, as determined by the ratio of N-acetyl aspartate to creatine, in the non-
epileptogenic hippocampi, the increased GABA is correlated with improved 
mitochondrial function (51). 
Microdialysis Studies in Animal Models of Epilepsy: 
 Results from microdialysis studies in animal models of epilepsy have been less 
consistent than the findings in humans. Some studies show an increase in glutamate 
during seizures (48, 54-59), while others indicate no change or even a decrease in 
glutamate (60-63). Many studies in rodents find an increase in GABA after seizure onset 
(59, 64, 65), although some have also shown a steady decrease (55, 66) or a brief increase 
followed by sustained decrease (67). This discrepancy may reflect the differences 
between chronic epilepsy in humans and the seizure models developed in animals and 
variations in the timing of microdialysate collection relative to convulsant infusion, as 
well as methodological differences between microdialysis in experimental animals and 
humans (including the development of substantial gliosis around chronically-implanted 
microdialysis catheters in animal models) (68). For example, pilocarpine injection is 
associated with an initial decrease in glutamate, which is followed by a sustained rise 
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associated with seizure activity, suggesting that the decrease is an artifact of the 
convulsant action (64). Wilson et al. were able to reproduce the ictal increases in 
glutamate and GABA seen in humans using a chronic rat kainate epilepsy model (48). 
Other chronic epilepsy models have borne out similar findings (69, 70).  
Basal neurotransmitter concentrations have also been examined in animal 
epilepsy models. Kaura et al. noted elevated basal ECF glutamate and glutamine and 
reduced basal GABA compared to controls in both the electrically-stimulated and 
contralateral amygdalae of kindled rats (71). Zhang et al. observed that basal glutamate 
remained elevated in the hippocampi of kindled rats for one to three months after the last 
electrical stimulation (72).  
Origins and Significance of Extracellular Glutamate, Glutamine, 
and GABA 
Whether the neurotransmitters detected in microdialysis studies are of neuronal, 
glial, or combined origin is controversial. The degree to which the extracellular 
concentrations of neurochemicals represent neuronal synaptic spillover or glial release is 
unknown (73).  The glutamate and GABA measured by microdialysis has been also 
proposed to represent volume transmission, a form of non-synaptic communication 
between neurons and astrocytes through the extracellular space (74). In earlier studies the 
insensitivity of extracellular glutamate to blockade of voltage-dependent sodium and 
calcium channels has suggested a non-neuronal source (73, 75), but the appearance of 
13C-enriched glutamate in the non-stimulated rat brain after injection of labeled glucose 
has also suggested at least a partial neuronal origin (76). Basal extracellular GABA is also 
insensitive to sodium channel blockade, suggesting a non-vesicular source (77).  
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Increasing evidence points to an astrocytic contribution to the elevated 
neurotransmitters observed in the ECF. Elevated extracellular glutamate and GABA may 
result from a reversal of astrocytic uptake due to changes in the ionic gradients that 
govern their respective cotransporters, specifically under conditions of energy deprivation 
(78). In the rat striatum, non-vesicular release by the cysteine-glutamate antiporter, which 
is predominantly glial, is thought to be the largest contributor to extracellular glutamate 
(79). This cysteine-glutamate antiporter is subject to feedback regulation by metabotropic 
glutamate receptors and the sodium-dependent glutamate transporter (79). Although 
originally thought to be limited to neurons, astrocytes can also release both glutamate 
(80) and GABA (81) in a calcium-dependent manner.  
It is postulated that extrasynaptic glutamate and GABA reflects an interaction 
between neurons and astrocytes that serve to modulate neuronal transmission through 
extrasynaptic receptors (74). Neuronal glutamate release, by activating astrocytic 
receptors, may stimulate astrocytic glutamate release, leading to an overall amplification 
of extracellular glutamate (82). This astrocytic glutamate release can induce paroxysmal 
depolarization in neurons, which has been proposed to contribute to seizure propagation 
(83). 
Finally, it is possible that the ictal or interictal increases in extracellular glutamate 
are due to changes in blood-brain barrier (BBB) permeability. BBB permeability is 
regulated by glutamatergic NMDA receptors (84) and permeability has been shown to 
increase in kainate-treated rats during seizures, coincident with the period of glutamate 
elevation (85). This suggests the possibility that elevated glutamate is a result of 
increased passage of its precursor, glutamine, through a leaky blood brain barrier.  
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Glutamate: 
Under normal conditions astrocytes tightly regulate the concentration of synaptic 
and extracellular glutamate through transport-mediated uptake. Extracellular glutamate is 
usually maintained at a concentration of approximately 1-2 µM, but can reach up to 1 
mM within the activated synapse (86). Dysregulation of extracellular glutamate probably 
increases susceptibility to seizures rather than provoking seizures directly. Chronic 
infusion of 1 mM glutamate in rats does not lead to electrographic changes, but an 
infusion of 200 µM glutamate before the convulsant picrotoxin lowers the seizure 
threshold and lengthens the seizure duration (87).  
Transporter dysfunction may contribute to the abnormal extracellular glutamate 
concentrations seen in epilepsy. While histologic studies on glutamate transporters in 
human TLE have been inconclusive (88), possibly confounded by the degree of neuronal 
loss, genomic and proteomic analysis of resected human neocortical epileptogenic tissue 
has identified reduced glutamate transporter expression (89). Reductions in transporters 
have been noted in animal models, including dogs with idiopathic familial epilepsy (90) 
and in a rat chronic seizure model (91). Inhibition of glutamate transport expression in 
rats results in elevated extracellular glutamate and is associated with the development of 
epilepsy and neuronal degeneration (92), which has implicated a role for glutamate 
transporter dysfunction in the pathogenesis of epilepsy. Elevated glutamate may impair 
its own clearance, since glutamate promotes the formation of reactive oxygen species 
(ROS), which can further impede glutamate transporter function (93). Although it is not 
known if this is related to transporter dysfunction or perturbed intracellular processes, an 
abnormal bioenergetic state, as measured by levels of PCr/ATP on magnetic resonance 
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spectroscopy, is associated with elevated glutamate (35). Therefore, increased energy 
demand or decreased energy availability may promote excitability. 
Excessive levels of glutamate are associated with neurotoxicity (94). Glutamate 
concentrations of 50-100 µM are toxic to neuronal cell cultures when applied for 5 
minutes (95). However, a higher glutamate concentration is required for toxicity in vivo 
in the presence of intact reuptake mechanisms (96). Glutamatergic excitotoxicity has 
acute and chronic components. The acute phase, which is sodium-dependent, is 
characterized by neuronal swelling that can progress to cell rupture if unchecked. The 
chronic phase, which is calcium-mediated, is associated with mitochondrial dysfunction 
leading to impaired glutamate reuptake and free radical damage (94). Excitotoxicity is 
enhanced in states of metabolic stress, such as ischemia or hypoglycemia (97), but is 
diminished in immature brains, possibly because the cell death pathway is undeveloped 
(56).  In a 4-aminopyridine rat model of epilepsy, the chronic elevation of glutamate for 
over 60 minutes has been demonstrated to result in an NMDA-receptor mediated 
neurodegeneration (98). In humans Cavus et al. have found that basal microdialysate 
glutamate levels greater than 5 µM are correlated with hippocampal atrophy, which may 
be evidence of glutamatergic neurotoxicity in human epilepsy (50). A similar glutamate 
concentration (5.8 µM) was indentified in the CSF of patients with ALS and found to be 
neurotoxic in cell culture (99). 
Glutamine: 
Although there is no evidence that glutamine participates in neuronal signaling, it 
is an important metabolic precursor of glutamate and GABA through the glutamate-
glutamine and GABA-glutamine cycles (51). In neurons the enzyme glutaminase 
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converts glutamine to glutamate and ammonia. After being released from neurons, 
glutamate is transported from the synapse into astrocytes, where it is converted to 
glutamine by glutamine synthetase (GS). Glutamine enters neurons, where it is converted 
to glutamate to complete the cycle. In GABAergic neurons, glutamate is converted to 
GABA via the enzyme glutamic acid decarboxylase (GAD). The regulation of glutamate 
and glutamine is closely coupled to the oxidative metabolism of glucose (100). 
 The ratio of glutamine to glutamate is lower in the epileptogenic compared to 
non-epileptic hippocampus, where glutamate is increased while glutamine is unchanged. 
This was seen in both the extracellular (49) and intracellular (101) hippocampal 
glutamate-glutamine ratio. A low glutamine-glutamate ratio suggests that glutamate is not 
being adequately converted to glutamine, as a result of dysfunction in both glutamate 
transport and GS. There is evidence of decreased GS in hippocampi affected by MTLE 
(102), which is proposed to lead to glial accumulation of glutamate. Interruption of 
glutamate-glutamine cycling could also vesicular GABA content (103). The resulting 
increased glutamate and decreased GABA may explain why blockade of glutamine 
synthetase in rats induces seizures (104). The epileptic brain may also preferentially 
convert excess glutamine to glutamate instead of GABA, as has been shown in tissue 
slices from the rat neocortical undercut epilepsy model (105).  
GABA: 
As the primary inhibitory neurotransmitter, GABA is involved in modulating 
seizures. Animal models with reduced GABA, either due to deficient precursors or 
impaired GAD, are prone to seizures (106). However, blockade of GABA synthesis will 
not increase excitability without simultaneous network activation (107). Epileptic patients 
16  
have reduced brain tissue GABA measured by magnetic resonance spectroscopy (MRS) 
compared to controls, and this deficiency extends to sites remote from the seizure focus 
(107). Low levels of brain GABA on MRS in patients with complex partial seizures are 
associated with a greater propensity to seize (107, 108), and increases in GABA after the 
addition of AEDs predict better seizure control (109). This association may not apply to 
patients with idiopathic generalized epilepsy, who exhibit lower brain GABA than those 
with complex partial seizures (107), even when receiving optimal seizure control from 
their AEDs (108).  
This reduction in GABA may be related to impaired transport. The population of 
GABAergic neurons is relatively intact in hippocampal sclerosis (110), and no significant 
changes in GAD, which synthesizes GABA, or GABA-transaminase, which catabolizes 
GABA, have been detected in the setting of chronic seizure activity (111). While GABA 
transporters usually remove GABA from the ECF, these transporters can operate in 
reverse, especially when intracellular GABA is elevated or under conditions of increased 
energy expenditure, such as seizures (112). Changes in GABA transporter function have 
been noted in humans with epilepsy and animal models. Microdialysis studies by During 
et al. in the hippocampi of patients with intractable TLE and in amygdala-kindled rats 
observed a reduction in transport-mediated glutamate-induced GABA release in both 
species, which was associated with reduced GABA transporter levels in the rat tissue 
(113). This may explain why their earlier-noted seizure-induced rise in extracellular 
GABA was greater in the contralateral than epileptogenic hippocampus (47). Forward 
and reverse transport of GABA is impaired in human tissue obtained from patients with 
mesial temporal sclerosis and in kainate-treated rats (114). Dysfunctional GABA 
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transport may diminish the compensatory increase in GABA in response to seizures, 
tipping the balance towards increased excitability and reduced inhibition.  
Several lines of evidence also indicate that within the epileptic brain sites, GABA 
may promote enhanced excitability rather than inhibition. In the healthy adult brain, the 
inhibitory function of GABA is dependent on a negative reversal potential for Cl-, which 
is regulated by the K+/Cl cotransporter (KCC2). However, addition of GABA to injured 
neurons in cell culture has been noted to induce outward Cl- flux and depolarization that 
could persist for two weeks (115). Decreased KCC2 function associated with a reversal in 
GABA potential and enhanced excitability has been also observed in rat hippocampal 
dentate granule cells after pilocarpine-induced status epilepticus (116), and may 
contribute to epileptogenesis. 
AED effects on Glutamate, Glutamine, and GABA 
 Although antiepileptic drugs often have multiple effects, their activity is broadly 
mediated through three main mechanisms: blockade of voltage-gated sodium and calcium 
channels, which limits action-potential-related neuronal vesicular glutamate release; 
blockade of glutamate receptors; and potentiation of GABAergic inhibition, through 
increasing GABA availability or modulating GABA receptors (117, 118). While much is 
known about their actions on neurons and within the synapse, less is known about their 
effects on extracellular neurotransmitter levels, especially in humans.  
MRS Studies on AED Effects 
Due to its non-invasive nature, magnetic resonance spectroscopy (MRS) has been 
employed in a number of in vivo human and animal studies to measure the effects of 
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AEDs on brain tissue levels of glutamate, glutamine, and GABA. While this process does 
not discriminate between intracellular and extracellular neurochemicals, most of the 
neurochemicals measured reflect the intracellular concentration of the neurochemicals, 
due to the negligible volume of the extracellular space. Elevated intracellular glutamate 
on MRS has been observed in the surgically resected human epileptogenic hippocampi 
(119) and cortex (120). As mentioned earlier, low brain GABA on MRS is associated 
with increased seizure frequency, presumably reflective of decreased inhibitory tone 
(107). An MRS study by Petroff and coworkers found increased glutamate or decreased 
GABA in 9 of our 14 patients with refractory epilepsy (121), suggesting that high brain 
glutamate and low brain GABA on MRS may be markers of poor response to AEDs. 
Effects of several AEDs on brain glutamate and GABA levels has also been examined 
using MRS. While phenobarbital (PB) and primidone (PMD) reduced the glutamate 
levels in epileptic patients, carbamazepine (CBZ), phenytoin (PHT), and gabapentin 
(GBP) had no effect (122). On the other hand, topiramate (TPM) (123), GBP (124), and 
vigabatrin (VGB) (125) increased the GABA levels in epileptic patients. TPM, GBP, and 
lamotrigine (LTG) also increase brain GABA levels in healthy subjects (126).  
AED effects measured by MRS may differ between humans and animal models. 
In a rat forebrain MRS study, GBP and pregabalin (PGB) decreased brain glutamate but 
did not affect brain GABA (127), while in humans GBP increased GABA (124, 126) but 
did not affect glutamate (122). An MRS evaluation of human and rat neocortical slices 
treated with GBP and PGB showed that PGB increased GABA in both the human and rat 
slices while GBP raised GABA only in the human tissue (128). It is important to 
emphasize that MRS results may not be analogous to microdialysis. While MRS results 
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reflect mostly the intracellular levels of the measured substrate, microdialysis samples the 
extracellular, and even more specifically, the extrasynaptic space. Therefore results 
obtained with one method can not be extrapolated to the other method. For example, 
gabapentin has not been shown to increase extracellular basal or stimulated GABA in the 
rat substantia nigra (129) even though it raises intracellular GABA. 
Microdialysis Studies of AED Effects in Animal Models 
Effects on Evoked Neurotransmitter Release 
The effects of AEDs on both the extracellular basal (interictal) and evoked 
(seizure-induced) levels of glutamate and GABA have been examined with microdialysis 
in rodent models in multiple studies, with some conflicting results. The effects of each 
medication on microdialysate glutamate and GABA concentrations are summarized by 
study for evoked conditions in Table 1 and for basal conditions in Table 2. The notable 
findings are summarized below. Multiple medications, including CBZ, diazepam (DZP), 
LTG, levetiracetam (LEV), PB, PHT, TPM, valproate (VPA), and zonisamide (ZNS), 
attenuated the seizure-induced rise in glutamate, which may reflect their effectiveness as 
anticonvulsants. With the exception of VGB and VPA, both of which inhibit GABA 
degradation, these medications also decreased the seizure-associated rise in GABA.  
Although many mechanisms overlap, CBZ, LTG, PHT, TPM, VPA, and ZNS block 
voltage-depended sodium channels; LEV inhibits release of synaptic vesicles; and DZP, 
PB, and TPM enhance chloride influx at GABA receptors (117, 118, 130), which may 
explain their reductions in presynaptic glutamate and GABA release.  
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Studies by different research groups on the same AED may have contradictory 
results that may be related to the animal model used, the relationship of medication 
administration to seizure, and the timing of microdialysate sample collection. For 
example, while one group (131) found no change in veratridine-evoked glutamate release 
after VPA administration, others (67, 132) observed a decrease in electroshock- and 
pilocarpine-evoked glutamate. The anatomical location sampled by the microdialysis 
probe may also affect the results. For example, CBZ, LTG, and oxcarbazepine (OXC) 
reduced evoked glutamate in the rat cortex but had no effect in the striatum (133). 
Effects on Basal Neurotransmitter Levels 
The effect of AEDs on basal extracellular glutamate and GABA levels is less 
consistent (Table 2). Multiple medications, including CBZ, DZP, and PHT, that have 
been demonstrated to diminish evoked neurotransmitter release appear to have no effect 
on basal levels. Inactivation of sodium channels by CBZ and PHT is use-dependent (130) 
and the reduction in presynaptic glutamate release by DZP may be depolarization-related 
(134). Even those AEDs that share a similar mechanism of action may have different 
effects on extracellular neurotransmitters. Ahmad et al. found that CBZ, LTG, and PHT 
affected basal and evoked glutamate and GABA differently, even though all three AEDs 
block sodium channels, which may suggest that their antiepileptic properties are mediated 
by other unknown mechanisms (135). Another possibility, suggested by Yoshida and 
Okada, is that the basal and evoked release of extracellular neurotransmitters are 
modulated by two different voltage-sensitive calcium channel complexes, which may 
explain why ZNS increases basal GABA but blocks evoked glutamate and GABA (136, 
137). 
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TGB, VPA, VGB, and ZNS increase basal GABA, which may reflect their 
mechanisms of action on GABA reuptake and degradation. TGB inhibits GABA uptake; 
VPA increases GABA synthesis and decreased its metabolism; VGB prevents GABA 
degradation; and ZNS increases GABA release (118). TPM, VPA and VGB can either 
increase or decrease basal glutamate depending on the dosage, anatomical site, and 
animal model studied. This may be related to the disinhibition of feedback control of 
glutamate levels (138). 
It is important to note that findings from animal models may not apply to humans 
and that multiple factors, such as dose and duration of administration, may modify drug 
activity. Different effects may occur at different doses. Peritoneal administration of VPA 
into rats at 100 mg/kg, which approximates the dose in humans, reduces hippocampal 
basal extracellular GABA by half, while 400 mg/kg valproate doubles it (139). The 
duration of AED administration may affect outcome, which is important because, in 
humans these medications are intended for chronic use. After chronic administration, 
LTG was less effective in reducing basal glutamate but more effective in attenuating the 
evoked glutamate increase in the rat hippocampus than when given acutely (140). 
Another concern in humans is the effect of multiple AEDs, which is especially relevant 
for the medication-refractory population, and several studies have addressed this in 
animals. Acute co-administration of VPA with LTG was more effective in decreasing 
basal glutamate and increasing basal GABA in the rat hippocampus then either 
medication alone (131). In some cases, the synergistic effects are different from the 
individual medication effects. The addition of a non-anticonvulsant dose of FBM to LTG 
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in mice increased whole-brain GABA and decreased evoked seizure activity, even though 
LTG alone decreased whole-brain GABA (141). 
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Table 1: Rat microdialysis studies of AED effects on evoked extracellular glutamate 
and GABA. 
AED Dose 
(mg/kg) 
Animal 
Model 
Probe Site GLU GABA Reference 
CBZ 5 Pilocarpine Hipp ↓ ↓ (142) 
CBZ 10-20 Veratridine Hipp ↔ ↓ (135) 
CBZ 30 Veratridine Hipp ↓ N/A (133) 
DZP 5 Pilocarpine Hipp ↓ ↔ (134) 
GBP 100 K+ S. N. N/A ↔ (129) 
LEV 100 K+, FeCl3 Hipp ↓ N/A (143) 
LTG 10 Pilocarpine Hipp ↓ ↓ (64) 
LTG 15 Veratridine Cortex ↓ N/A (133) 
LTG 10-20 Veratridine Hipp ↓ ↓ (135) 
LTG+
VPA 
10+300 Veratridine Hipp ↔ ↑ (131) 
OXC 60 Veratridine Cortex ↓ N/A (133) 
PB 15 Pilocarpine Hipp ↓ ↓ (142) 
PHT 20-40 Veratridine Hipp ↔ ↔ (135) 
PHT 20 Max E-shock Hipp ↓ ↔ (67) 
TPM 200 Pilocarpine Hipp ↓ ↓ (144) 
VPA 300 Veratridine Hipp ↔ ↑ (132) 
VPA 400 Pilocarpine Hipp ↓ ↓ (132) 
VPA 400 Max E-shock Hipp ↓ ↑ (67) 
VGB 30 Pilocarpine Hipp ↓ ↑ (145) 
ZNS N/A K+ Hipp ↓ ↓ (137) 
AEDs are generally administered intraperitoneally or orally, except for N/A doses, which are 
infused hippocampally. Abbreviations: CBZ, carbamazepine; DZP, diazepam; GBP, gabapentin; 
LEV, levetiracetam; LTG, lamotrigine; Max E-shock, maximal electroshock; PB, phenobarbital, 
PHT , phenytoin; S. N., substantia nigra; TPM, topiramate; VPA, valproic acid; VGB, vigabatrin, 
ZNS, zonisamide. 
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Table 2: Rat microdialysis studies of AED effects on basal glutamate and GABA. 
AED Dose 
(mg/kg) 
Animal 
Model 
MD Probe Site GLU GABA Reference 
CBZ 10-20 Normal Hipp ↔ ↔ (135) 
DZP 5 Normal Hipp ↔ ↔ (134) 
GBP 100 Normal S. N. N/A ↔ (129) 
LEV 40, 80 Normal Hipp, Frontal 
CTX  
↔ ↔ (146) 
LTG 10 Normal Hipp ↔ ↔ (64) 
LTG 20 Normal Hipp ↓ ↔ (135) 
LTG+
VPA 
10+300 Normal Hipp ↓ ↑ (131) 
PB 15 Normal Hipp ↔ ↔ (142) 
PHT 20-40 Normal Hipp ↔ ↔ (135) 
PHT 20 Normal Hipp ↔ ↔ (67) 
TGB 11.5, 21 Normal Basal ganglia N/A ↑ (147) 
TPM 200 Normal Hipp ↑ ↓ (144) 
TPM 40 Normal Hipp ↔ N/A (148) 
TPM 40 SER Hipp ↓ N/A (148) 
VPA 300 Normal Hipp ↔ ↑ (131) 
VPA 400 Normal Hipp ↑ ↔ (132) 
VPA 400 Normal Hipp ↔ ↑ (67) 
VPA 400 Normal Hipp ↔ ↑ (139) 
VGB N/A Normal Striatum ↑ ↑ (138) 
VGB 30 Normal Hipp ↓ ↔ (145) 
VGB 1000 Normal Frontal CTX N/A ↑ (149) 
VGB 1000 Normal Hipp N/A ↔ (149) 
ZNS N/A Normal Hipp ↔ ↑ (137) 
 
AEDs are generally administered intraperitoneally, except for N/A doses, which indicates 
hippocampal or striatal infusion.  “Normal” model indicates rat not otherwise predisposed to 
epilepsy before convulsant administration. Abbreviations: CBZ, carbamazepine; CTX, cortex; 
DZP, diazepam; GBP, gabapentin; LTG, lamotrigine; PB,  phenobarbital, PHT , phenytoin; SER, 
spontaneously epileptic rat;  S.N., substantia nigra; TGB, tiagibine; TPM, topiramate; VPA, 
valproic acid; VGB, vigabatrin, ZNS, zonisamide. 
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In Vitro Studies on the AED Effects of Neurotransmitter Release 
AED effects on neurons have also been explored in vitro in synaptosomes and 
brain tissue slices. Synaptosomes may accurately reflect AED effects on neurotransmitter 
release, but may not be comparable to microdialysis results, since the degree of synaptic 
contribution to the neurotransmitter levels in the ECF is disputed (73). CBZ, PHT, LTG, 
and OXC, which block sodium channels, reduce glutamate release in isolated veratridine-
stimulated nerve endings, while TPM and PB had minimal effects on glutamate (150, 
151). Under resting conditions, CBZ, PHT, LTG, OXC, and TPM did not affect basal 
glutamate release from synaptosomes (151). VPA increased GABA levels in 
synaptosomes and tissue slices (152), similar to its findings in microdialysis studies. In 
rat entorhinal cortex slices, LTG (153) and PHT (154) decreased basal glutamate and 
increased basal GABA release. However in rat amygdala slices, LTG at similar 
concentrations slices decreased spontaneous and evoked GABA release (155).  Analysis 
of whole-brain homogenate, which is similar in principle to MRS, may also not 
accurately predict microdialysis results. TPM (156) and LEV (157) administration had no 
effect on whole brain glutamate or GABA in rats.  
AED Effects on Neurotransmitter Transport and Metabolism 
In addition to their direct action on neuronal transmitter release, AEDs may also 
exert their effects through regulation of neurotransmitter transport and synthesis. LEV 
(143), VPA (158), ZNS (159) have been shown to upregulate glutamate transporters; for 
LEV this upregulation has been shown to be associated with a reduction in evoked 
extracellular glutamate (143). While LEV has been reported to upregulate the GABA 
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transporter GAT-3 (143), VPA (158) and ZNS (159) were reported to downregulate 
GABA transporters. Although GABA transporter regulation was not directly correlated 
with levels of extracellular GABA in those studies, there is evidence that VPA (67, 131, 
139) and ZNS (137) increase basal GABA. Mechanisms underlying GABA increases 
vary by AED: TGB inhibits GABA reuptake (160), VGB blocks the degradative enzyme 
GABA-transaminase (161), and VPA stimulates GABA synthesis while decreasing 
catabolism (162). 
 AEDs also affect glutamine metabolism, either by increasing precursor or 
interacting with synthetic enzymes. This is important, because glutamine is in balance 
with glutamate and GABA, through the pathways discussed earlier. TPM (163), VPA 
(121) and VGB (164) increase brain glutamine in human in vivo MRS studies. In the case 
of VPA, the increase in whole-brain glutamine may result from drug-induced 
hyperammonemia, due to disruption of the urea cycle, which stimulates GS and inhibits 
glutaminase in the brain (165). However, a rat microdialysis study did not find any 
change in glutamine after VPA administration (139), which suggests either that rodents 
respond differently to VPA or that the intracellular increase in glutamine seen on MRS is 
not detected extracellularly. Other causes of increased glutamine may include 
normalization of glutamate-glutamine cycling (164) or changes in GABAergic 
neurotransmission (163). Finally, some drugs affect GS directly. Chronic administration 
of PHT, CBZ, PB, FBM, and TPM in mice has been shown to reduce GS activity, while 
VPA, VGB, LTG, GBP, TGB, and LEV were not found to affect GS (166).  
27  
Summary of AED effects: 
 The effects of antiepileptic drugs on glutamate and GABA have been explored 
through MRS in humans, microdialysis in rats, and in isolated synaptosomes. The 
findings of each of these methods may be different from microdialysis in humans: MRS 
assesses whole-brain concentrations, which are predominantly intracellular; animal 
models may poorly approximate results in humans; and synaptically-released 
neurotransmitter may not be a significant constituent of microdialysate. Also, it is 
important to recognize that drug effects on neurochemicals during seizures may be 
different from drug effects under basal conditions. For example, CBZ and PHT, which 
block sodium channels, suppress evoked glutamate and GABA in rats (67, 142), but do 
not decrease intracellular glutamate in humans (122) or reduce basal glutamate in 
synaptosomes (151) or in animal microdialysis (135). Medications that increase GABA 
appear to have consistent effect across different studies. VGB is shown to increase 
GABA in human MRS (125), synaptosomes (167), and in rat evoked (145) and basal 
(149) microdialysis studies. VPA increases GABA release in synaptosomes (152) and 
basal and evoked rat microdialysis (67), but did not have an effect on whole-brain GABA 
in a human MRS study (121). It may also be possible that AEDs mediate their effects 
through other mechanisms that have not been previously explored, such as decreasing the 
excitability of astrocytes (83). 
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AED Distribution and Resistance 
Microdialysis studies on AED Levels in the Brain 
In addition to detecting changes in neurotransmitter concentrations, microdialysis 
can be also used to measure the levels of the AEDs. Since microdialysis measures the 
concentration of free, unbound AED in the brain, it assesses the fraction of whole-brain 
drug that is functionally significant (168). Drug concentrations are often estimated by 
their levels in serum or cerebrospinal fluid (CSF), but these do not always reliably predict 
ECF drug levels, because the blood-CSF barrier is often more permeable that the blood-
brain barrier (169). Early microdialysis studies in a limited number of subjects with drug-
refractory epilepsy reported that the ECF concentrations of CBZ (170) and PHT (171) in 
the hippocampus reflected their unbound serum concentrations. However, a study in eight 
patients with head injury found that although in individual patients the serum PHT 
concentration correlated with the concentration in the ECF, this ratio was unique to each 
patient, and there was no universal ratio between serum and ECF concentrations (172). In 
humans with medically refractory epilepsy, the AED concentrations in the ECF have 
been shown to be lower than their respective concentrations in CSF and in the resected 
brain tissue (173). In animals, the ECF concentrations of LTG (169), PHT (174), and 
TGB (175) follow different kinetics than their serum concentrations, often enabling 
greater stability in their brain compared to serum concentrations. 
Within the brain ECF, drug concentrations may differ between brain regions and 
even within the same region. Some AEDs, such as LTG (169), TGB (175), and LEV 
(146) are evenly distributed between frontal cortex and hippocampus in rats. However, 
PHT concentrations are higher in the hippocampus (176), and VGB is higher in the 
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frontal cortex (149). This may be due to differences in white matter content, regional 
blood flow, and drug transporter expression. The differences in concentration may affect 
the effects of AEDs on target neurotransmitters. In VGB-treated rats basal GABA 
increased five-fold in the frontal cortex but was unchanged in the hippocampus, 
reflecting their respective drug concentrations in these regions (149). Rambeck and 
colleagues intraoperatively examined the concentrations of CBZ, OXC, LTG, LEV, 
TPM, and PHT in the middle temporal gyrus of refractory epilepsy patients and found 
that concentrations could differ markedly within the same patient, even though the MD 
probes were located 0.6 cm apart (173). Although differences in probe fractional 
recoveries may account for these findings, these data may also suggest evidence for 
influence of drug efflux transporters on AED concentration. 
Drug Efflux Transporters 
The most commonly studied efflux transporters, P-glycoprotein (P-gp) and the 
multidrug resistance proteins (MRPs), are members of the adenosine triphosphate-
binding cassette (ABC) family of transporters and are expressed heavily in excretory 
organs and in blood-tissue barriers, including the blood-CSF and blood-brain barriers (14, 
177). These transporters have been shown to be over-expressed in epileptogenic tissues, 
such as in the hippocampal sclerosis (178, 179), focal cortical dysplasia (179, 180), and 
cortical tubers (181). It has been suggested that increased expression of drug transporters 
in epileptic regions may confer a cell survival advantage in the setting of impaired 
homeostasis, since apoptosis is rarer in epilepsy than would be expected (182). 
It is unclear if the increased drug transporters are constitutive or are induced by 
drugs or seizures. While administration of some AEDs is associated with efflux 
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transporter induction in human cell lines (183) and human duodenum (184), no increases 
have been observed in non-epileptic rats treated with PB (185), PHT (185, 186), or CBZ 
(186). Increases in efflux transporters, however, have been noted after evoked seizures in 
rats (187, 188) and in human brain following a fatal attack of status epilepticus (189). 
Interestingly, in the human post-mortem study, efflux transporters were upregulated in 
the histologically normal brain as well as dysplastic focus (189). The seizure-induced 
expression of P-gp may be directly related to increased extracellular glutamate. 
Glutamate applied directly to isolated rat brain capillary endothelial cells has been shown 
to increase expression of P-gp (190), and blockade of glutamate receptors prevents in 
vivo P-gp accumulation in rat brain capillary endothelial cells after pilocarpine-induced 
seizures (191). P-gp has been shown to mediate glutamate efflux through the BBB in rats 
(192), and it is possible that the increased expression of P-gp is a defense against 
glutamatergic neurotoxicity, although its role in regulating extracellular glutamate in 
humans with epilepsy is unknown. 
The therapeutic implications of these upregulations in P-gp and MRPs are 
currently under investigation. Neuroectodermal cell lines expressing MDR1 have 
decreased intracellular phenytoin compared to MDR1-negative cells, suggesting that the 
overexpression of efflux transporters in epileptogenic tissue may prevent adequate AED 
concentration (178). In animal studies the effect of efflux transporters on AED levels by 
pharmacologic transporter blockade with verapamil or nimodipine for P-gp and with 
probenecid for MRP. Using these methods, inhibition of P-glycoprotein is associated 
with reduced brain ECF levels of CBZ, LTG, FBM, OXC, PB, and PHT in rats (193-
196). LEV (197) and VPA (198) do not appear to be regulated by P-gp or MRPs in rats. 
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However, one must be cautious in applying animal data to humans. It has been shown 
that kidney cells transfected by human MDR1 and MRP2 are significantly less effective 
in transporting AEDs than those transfected by their rat counterparts, although this 
difference has not been examined in brain tissue (199). On the other hand, there is 
evidence in humans of improvement of refractory epilepsy after the addition of verapamil 
to the existing AED regimen (200, 201), although this may reflect an intrinsic 
antiepileptic property of verapamil-mediated calcium blockade rather than efflux 
transporter disruption. If efflux transporters are involved in AED medication 
refractoriness, it may explain why resistance to one antiepileptic drug is associated with 
resistance to others (202). Unfortunately, this will be difficult to prove in humans because 
microdialysis and tissue studies are conducted exclusively in drug-refractory patients, 
making it impossible to make comparisons with normal controls and patients with drug-
responsive epilepsy (173). 
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Statement of Purpose 
The technique of microdialysis in conscious human subjects undergoing 
intracranial EEG monitoring has made it possible to explore the neurochemical substrates 
(i.e. glutamate, glutamine, and GABA) of drug-resistant epilepsy, both ictally and 
interictally, and to characterize the differences between epileptic and non-epileptic brain 
regions. To date these extracellular neurochemicals have not been evaluated in regions of 
seizure propagation, MRI-identified lesions, and patients with non-localizable seizure 
onset. In addition the effect of antiepileptic medications on the extracellular levels of 
these neurochemicals has not been previously considered in humans. Due to the poor 
response of some epilepsies to treatment (2) and the significant costs associated with 
medication-resistance (4, 5), it is essential to better understand the neurochemistry and 
response to treatment of medication-refractory epilepsy. Since epileptogenesis may be 
distributed beyond the seizure onset site (22, 23) and electrographic (25) and metabolic 
abnormalities (203) distant from the seizure focus predict poor surgical outcome, it is 
important to study the extracellular milieu of the seizure propagation pathways. Although 
microdialysis studies on AED effects on glutamate and GABA have been conducted in 
animals, several of these studies report contradictory results and findings in animals may 
not apply to humans. Glutamate increases occur with seizures (47, 48) and elevated basal 
glutamate is associated with hippocampal atrophy (50), which implies that an 
understanding of the medication effects may guide further treatments directed specifically 
at extracellular glutamate (204). 
This thesis will first explore the differences between epileptic, propagated, and 
non-epileptic hippocampus, cortex, and lesions with regard to the basal extracellular 
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levels of glutamate, glutamine, and GABA building on previous work by Cavus and 
colleagues that demonstrated a difference in glutamate between the epileptogenic and 
non-epileptic cortex and hippocampus (49). It is hypothesized that basal glutamate will 
be elevated in epileptogenic, non-localized, and lesion sites due to their association with 
seizure onset. Propagated sites, though exposed to frequent epileptic activity, presumably 
have intact glutamate regulation and are postulated to have only mild elevations in 
glutamate. If basal GABA levels reflect a response to frequent seizure activity, GABA 
would be expected to be most elevated in the propagated sites, which are involved in 
seizure spread after initiation elsewhere. GABA may be less elevated in epileptogenic 
sites, non-localized sites, and lesions, since the GABAergic response to frequent seizure 
activity may be impaired in these regions. Finally, GABA may be low in non-epileptic 
sites due to their lack of electrical activity and, presumably, of underlying pathology. 
Finally, the effects of anti-epileptic drugs on these neurotransmitter levels will be 
explored by comparing the basal levels of glutamate, glutamine, and GABA, when the 
patients are their full or near-full dose of AEDS and after the AEDs are tapered, as per 
the inpatient monitoring protocol. It is hypothesized that medication taper will induce an 
increase in basal glutamate and a decrease in basal GABA, since many of these 
medications exert their anti-epileptic effects by reducing excitatory and enhancing 
inhibitory tone. If AEDs promote the production of glutamine over glutamate, then AED 
withdrawal may be expected to decrease basal glutamine. However, since all of our 
subjects have medically refractory epilepsy, in which the effects of AEDs are presumably 
impaired, then the taper effect may be less pronounced than expected and vary by site. 
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Methods 
Patient Selection 
 All subjects were patients with medication-resistant complex partial seizures 
undergoing intracranial electroencephalographic evaluation for identification of their 
seizure focus prior to consideration for resective surgery. By this point these patients had 
already completed the less invasive stages of the three-phase workup algorithm (205). In 
Phase I, patients were evaluated as inpatients in the epilepsy unit via continuous audio-
visual (AV) recording in concert with scalp EEG. These recordings were frequently 
accompanied by magnetic resonance imaging (MRI), ictal and interictal cerebral blood-
flow evaluation with single-photon emission computed tomography (SPECT), cerebral 
metabolic assessment with positron emission tomography (PET), and neuropsychological 
evaluations in order to non-invasively identify the seizure focus. Phase II consisted of the 
intracarotid sodium amobarbital procedure, or Wada test, to identify the dominant 
hemispheres for language and memory in preparation for resective surgery. Those 
patients in whom a seizure focus could not be identified or for whom the collected data 
were inconsistent with regard to seizure onset localization were considered for a Phase III 
study, which consists of continuous AV-icEEG recording obtained from intracranial 
electrodes (IC) through a combination of subdural strip, grid, and depth electrodes 
implanted in regions of suspected seizure onset. Patients undergoing Phase III evaluation 
between 1998 and the present have been invited for participation in the microdialysis 
research protocols, as approved by the Yale Human Investigations Committee in 
compliance with the Declaration of Helsinki. Brain microdialysis data were collected 
only from consented subjects. Data for the basal neurochemical comparisons in the 
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hippocampus and cortex were collected between 1998 and 2008, corresponding to the 
period of neurochemical concentration analysis by HPLC. Data for the AED taper 
comparisons were collected between 2002 and 2008. 
Microdialysis probes and procedures 
Patients were implanted with microdialysis probes coupled to depth electrodes 
(Spencer probe, Ad-Tech Instrument Co, Racine, WI) under stereotactic guidance 
(BrainLab, Westchester, IL) in sites of suspected seizure onset, which include cortex, 
hippocampus, and lesions. All surgeries were performed by Drs. Dennis Spencer, 
Kenneth Vives, and members of the Yale Department of Neurosurgery. Two types of 
microdialysis probes have been used.  Prior to 2003, the Spencer probe was employed, 
which consisted of a 10 mm membrane of 0.3 mm diameter with a 5 kDa cutoff, attached 
with epoxy adhesive to a flexible depth electrode. See  (47, 49, 68) for details. More 
recently, a modified CMA/20 probe (CMA, North Chelmsford, MA) of 70 mm probe 
length with a 10 mm membrane of 0.67 mm diameter with 20 kDa cutoff has been used. 
See (50) for details. The CMA probe was inserted into the depth electrode (total diameter 
= 1.85 mm) and fluid exchange occurred through perforations located between electrical 
contacts 1 and 2. The location of each the probe was confirmed by a postoperative co-
registered CT/MRI.  
Following implantation surgery and 1-2 days post-op recovery in the intensive 
care unit, subjects were transferred to the epilepsy unit on their full outpatient AED dose 
for AV-icEEG monitoring. AED taper was then initiated in order to allow for the 
occurrence of spontaneous seizures. The nature and rate of the AED taper was dictated by 
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clinical needs. In order to avoid triggering atypical withdrawal seizures, benzodiazepines 
and barbiturates were not tapered (30). Usually, satisfactory icEEG data were obtained 
for sufficient seizure localization over 1-2 weeks. AEDs were then increased to their pre-
op dose, and, in a subsequent surgery, all intracranial electrodes were removed.  Usually 
resective surgery (Phase IV) was performed in another scheduled session.  
Classification of microdialysis probe sites: 
Probes were classified according to their location in the hippocampus and cortex 
by the post-operative CT-MRI. Probes located in the thalamus and basal ganglia were 
excluded due to the lack of a sufficient number of similar probes for a group analysis. 
Following our microdialysis study group’s methodology of averaging data from probes 
located in the same structure (50), which reflects the surgical convention of resecting the 
entire diseased hippocampus or lesion whenever possible, data from probes located in the 
same hippocampus or lesion with the same electrographic properties (i.e. non-epileptic, 
epileptogenic, and propagated) were averaged.  
The epileptogenicity of the region sampled by the microdialysis probe coupled to 
a depth electrode was determined based on the conclusions of the Epilepsy Surgery 
Program conference, with decisions rendered by a consensus of epileptologists 
independent from the microdialysis program, incorporating all available clinical, icEEG, 
imaging and neuropsychological data. Probes were classified as epileptogenic if the 
seizure originated from either contact 1 or 2 of the depth electrode flanking the 
microdialysis membrane, propagated if the site was immediately involved after seizure 
onset by demonstrating abnormal rhythmic epileptiform activity before seizure 
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generalization, and non-epileptic if the site was not involved in seizure onset or any stage 
of propagation. If a single seizure onset could not be determined and patient was deemed 
to be non-localizable, then all probes for that patient were classified as non-localized. 
Cortical probes located in non-neoplastic structural abnormalities identified on MRI were 
classified as lesion, which included dysplasias, heterotopias, and cortical tubers. Six 
patients with tumors (astrocytoma or ganglioneuroma) were excluded. Probes of 
questionable anatomic location or electrical activity were excluded. Demographic and 
patient history data were obtained from a chart review and structured patient interview. 
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Figure 1: Microdialysis probes and their implantation. A) Spencer depth electrode 
beside a modified CMA/20 microdialysis catheter (CMA, North Chelmsford, MA). B) 
Spencer depth electrode with the microdialysis catheter inserted as arranged prior to 
implantation. C) Intraoperative view with subdural grid, strip, and depth electrodes. The 
microdialysis catheter is inserted in the depth electrode marked by the black arrow. D) 
An MRI reconstruction showing bilateral hippocampal depth electrodes. The 
microdialysis membrane is located between the first two electrical contacts. Data from 
the two probes in the right hippocampus would be averaged. E) Cortical probes in the left 
orbitofrontal and cingulate cortices. F) Microdialysis probe within a lesion: here, in 
cortical dysplasia adjacent to a previous resection. 
 
Zero-flow Microdialysis Method 
All basal samples were obtained via the zero-flow quantitative microdialysis 
method, which was used to estimate the true basal neurotransmitter concentrations in the 
extracellular space (40, 42). To avoid any confounding effects due to blood-brain barrier 
disruption from implantation, anesthetics, circadian rhythm, and seizures, the first zero-
flow collection was conducted 2-4 days after probe implantation in the afternoon while 
patients were quietly resting, at least 4-6 hours from any seizure activity. In many recent 
patients (since 2002), multiple basal collections have been performed during the same 
inpatient stay, often 2-3 days apart, under the same conditions. Sterile artificial 
cerebrospinal fluid (135 nM NaCl, 3 mM KCl, 1 mM MgSO4*7H2O, 1.2 mM 
CaCl2*2H2O in 1 mM sodium phosphate buffer at pH 7.4) was infused using CMA107 
syringe pumps (CMA, North Chelmsford, MA). After allowing for equilibration between 
flow rate changes, two samples were obtained each at 2.0, 1.0, 0.5, and 0.2 µL/min flow 
rates. The collected dialysate samples were stored over dry ice and then in a -80 ºC 
freezer for future high-performance liquid chromatography (HPLC) analysis. Basal levels 
were determined using regression analysis of the concentrations obtained at the different 
flow rates with a 2nd order polynomial fit and extrapolation to a flow rate of zero. Data 
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from 53 out of a total of 89 included subjects were collected over a period of 6 years 
using the zero flow method. It has been demonstrated that microdialysis collection at a 
very low flow rate of 0.2 µL/min reliably allows for 80% recovery of the concentration of 
substrates estimated with the zero flow method (40, 42). Because the zero-flow method is 
very cumbersome, often taking 6 hours to complete, in more recent studies (since May 
2004) involving 36 of 89 included subjects, this very low-flow microdialysis method was 
adopted. For this technique one 0.2 µL/min sample was collected over 1.5-2 hours, and, 
following HPLC analysis, the obtained value was corrected for 80% recovery to 
determine the basal concentration. Microdialysate was collected by M. Cassaday, D. 
Ocame, S. Forselius, W. Kassoff, G. Widi, and myself. 
For the first analysis, which compared non-epileptic, epileptic, propagated, lesion, 
and non-localized probes within the hippocampus and cortex, only the first basal 
microdialysis collection (on the full AED dose) was used for each patient. The second 
analysis, which examined the effects of medication taper, was restricted to the subset of 
patients who had at least two basal collections. The first basal collection (B1) was 
collected while on the full dose AED dose, while the second basal collection (BTap) was 
collected after the medications were tapered. For our analysis, we chose the basal 
collection closest to the point of maximum drug taper to be BTap and required that there 
had been a 50% reduction in at least one AED from the dose at B1 (the full outpatient 
dose) within the 24 hours preceding collection. Medication status was verified by a chart 
review of daily inpatient medications and, if available, blood medication levels. While 
the actual AEDs and dose reductions involved in the taper differed between patients, 
clinically, the taper period was frequently related to increased seizure activity. 
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Neurochemical Concentration Determination 
 Glutamate and glutamine were analyzed by high-performance liquid 
chromatography (HPLC) (49). One µL of sample was mixed with 9 µL aminoadipic acid 
(AAA) internal standard and derivatized by adding 20 µL of O-phthaldialdehyde. Twenty 
µL of the derivatized sample was then injected into the HPLC column (3 m Phase II ODS 
column, 3.2 X 100 mm cartridge, Bioanalytic Systems, Inc., W. Lafayette, IN). The 
mobile phase was comprised of 0.1 M acetic acid (pH 6.0) with acetonitrile gradient from 
12 to 20% flowing at 1 mL/min. The fluorescence detector (Shimadzu Scientific 
Instruments, Columbia, MD) was set with excitation wavelength 338 nm and emission 
wavelength 425 nm. Peaks occured at approximately 6.9 minutes for glutamate, 7.7 
minutes for AAA, and 8.8 minutes for glutamine (Figure 2). Sensitivity limits were 0.1 M 
for glutamate and 10 M for glutamine, based on a signal to noise ratio of 10:1. The 
concentrations of amino acids were calculated by comparing their peaks to the external 
standard using EZCHROME elite software (Scientific Software, Inc., Pleasanton, OH).  
GABA was analyzed on a separate system (Bioanalytic Systems, Inc., 
Indianapolis, IN) (50). 2 µL dialysate was mixed with 4 µL internal standard (2-amino-n-
valeric acid) and derivatized with 13 µL O-phthaldialdehyde. This mixture was then 
injected into a column (BAS, ODS column, Phase II 100 X 3.2 mm 3 µm) with mobile 
phase of 0.1 M acetic acid (pH 4.85) in 37% acetonitrile solution flowing at 0.8 mL/min. 
Peaks were detected electrochemically (ESA, Chelmsford, MA, USA) at 43 mV with 
sensitivity limit 8 nM. The concentration was determined by comparing neurochemical 
peaks to the standard using EZCHROME elite software. HPLC analysis was performed 
by M. Cassaday, D. Ocame, G. Widi, and myself. 
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Figure 2: High performance liquid chromatogram showing peaks for aspartate, 
glutamate, α-aminoadipic acid (the internal standard) and glutamine (from Cavus et 
al., 2005). 
 
Statistical Analysis 
The concentrations for all three neurochemicals measured were positively 
skewed; therefore these values were-log-transformed to normalize them for statistical 
analysis. All statistics were calculated on the log-transformed data using SAS (SAS 
Institute, Cary, NC). Since many subjects had multiple microdialysis probes, it was 
necessary to determine whether there was a significant within-patient effect on the 
measured concentrations. For the purposes of this analysis, each intracranial study (n = 
89), rather than individual patient (n = 81), was treated as a separate subject, because 
repeat intracranial studies were conducted months or years after the initial study under 
different sampling conditions (including time since last seizure, AED dose, background 
brain activity, etc.). The log-transformed data were modeled with a two-level nested data 
structure by probes within subjects. Between-subject and between-probe variations were 
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modeled using appropriate variance and covariance components. For the first analysis, 
the log-transformed concentrations of glutamate, glutamine, and GABA from the first 
basal collection were compared by group within the hippocampus and cortex using 
hierarchical linear modeling. Significance was set at p < 0.05. If there was a significant 
difference between groups, comparisons between groups were made by multiple t-tests 
with a Bonferroni correction for significance (3 comparisons in the hippocampus and 10 
comparisons in the cortex). P-values are reported in their Bonferroni-adjusted forms (i.e. 
multiplied by the number of comparisons), where appropriate. Results are reported as 
arithmetic mean ± standard error of the mean (SEM).  
The concentrations of glutamate, glutamine, and GABA were compared between 
the hippocampus and cortex within the three shared groups (non-epileptic, epileptic, 
propagated) by paired 2-tailed t-tests, and if there were no significant differences, the 
probes from the hippocampus and cortex were combined within each group for the 
medication taper analysis. 
For the medication taper analysis, log-transformed data were modeled using the 
same two-level nested data structure by probes within subjects. This probes-within-
subjects effect was found not to be significant. The log-transformed concentrations of 
glutamate, glutamine, and GABA were compared between B1 and BTap within each probe 
category by a paired t-test with a Bonferroni correction for 5 comparisons to determine if 
there was a significant change in concentration with taper. Then, the difference in log-
transformed concentration between BTap and B1 was compared between probe categories 
by fixed-effects ANOVA, to determine if there was an interaction of category with the 
main effect of medication taper (i.e. if different probe categories responded differently to 
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taper). If the ANOVA indicated a significant interaction for given neurochemical, the 
log-transformed changes in concentration were compared between categories by a post-
hoc Tukey’s test. 
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Results 
I. Subjects and Microdialysis Probes 
Altogether, 91 patients implanted with 202 microdialysis probes were studied 
between October 1998 and December 2007. In accordance with our predefined exclusion 
criteria, 37 probes were excluded from the final analysis: 14 due to their location outside 
of the hippocampus or cortex (amygdala, n=5; thalamus, n=3; basal ganglia, n=2; 
ventricle, n=2; corpus callosum, n=1; and internal capsule, n=1), 8 due to their location in 
patients with tumors, 6 with missing neurochemical data, 4 with unclear probe 
epileptogenicity or location, and 3 with too few probes for a separate group analysis (all 
hippocampal in non-localized patients). 
A total of 81 patients (38 males and 43 females) were included in the final 
analysis. These patients were 32.5 ± 9.91 (mean ± SD) years of age and had experienced 
recurrent seizures for an average of 18.9 ± 10.6 years prior to intracranial evaluation. 
Data were collected from 165 microdialysis probes implanted in 89 separate intracranial 
studies (Figure 3). The number of intracranial studies is greater than the number of 
patients, because some patients with inadequate initial studies required repeat intracranial 
electrographic evaluations: six patients underwent two intracranial studies and one patient 
required three studies. The first basal collection was obtained interictally 2.7 ± 1.6 days 
(mean ± SD) after probe implantation while patients were on AED doses similar to their 
outpatient regimen. 
Of the included probes, 57 were located in the hippocampus and 108 were in the 
cortex. Ten hippocampi had 2 probes, which were averaged, resulting in 47 hippocampal 
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sites. Similarly, 2 probes located in the same cortical dysplasia lesion were averaged, 
resulting in 107 cortical sites. No probes located in the non-lesional cortex were 
averaged, as they were all located in separate cortical regions. Because of this probe 
averaging, all data are hereafter reported by site. 
Cortical and hippocampal sites in patients with localizable seizure onsets were 
then further organized by seizure activity into: non-epileptic hippocampus (n = 17), 
epileptogenic hippocampus (n = 22), propagated hippocampus (n = 8), non-epileptic 
cortex (n = 29), epileptogenic cortex (n = 9), and propagated cortex (n = 33). Twenty 
probes were located in the cortex of subjects (n = 21) with non-localizing intracranial 
EEG studies, largely comprised of individuals with multifocal epilepsy, and were all 
classified as non-localized.  Fifteen probes were located in non-neoplastic developmental 
or acquired lesions identified on imaging, representing 6 dysplasias (including the 
average of 2 probes), 4 heterotopias, 3 encephalomalacias, and 2 cortical tubers. 
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Figure 3: Flow-chart of microdialysis probe inclusion and classification within the 
hippocampus and cortex for the single basal analysis. *The number of subjects is 
greater than the number of patients, because several patients underwent multiple 
intracranial studies, which were treated separately. **Data from probes located in the 
same structure (hippocampus or lesion) were averaged to represent a single site. 
 
II. Basal Glutamate, Glutamine, and GABA in the Cortex and 
Hippocampus 
The mean levels of extracellular glutamate, glutamine, and GABA were compared 
within the cortex among non-epileptic, epileptogenic, propagated, non-localized, and 
lesion sites and within the hippocampus among non-epileptic, epileptogenic, and 
propagated sites (Table 3). The within-subject effects for glutamate, glutamine, and 
GABA were significant. Consequently, the within-subject effect was retained in the 
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statistical model for all three neurochemicals. All p values related to comparisons 
between sites are reported after Bonferroni-adjustment. 
Probe Site # Sites Glutamate (µM) 
Glutamine 
(µM) 
GABA 
(nM) 
Cortex 107    
Non-epileptic  29 2.6 ± 0.3 721 ± 124 265 ± 62 
Epileptogenic  9 17.3 ± 5.1* 818 ± 152 921 ± 456 
Propagated  33 25.8 ± 4.0* 669 ± 108 1503 ± 273* 
Non-localized  21 43.9 ± 9.9* 801 ± 187 720 ± 172 
Lesion 15 46.9 ± 9.0* 1181 ± 176 827 ± 183* 
Hippocampus 47    
Non-epileptic 17 2.8 ± 0.5 482 ± 55 391 ± 169 
Epileptogenic  22 10.3 ± 1.9* 557 ± 75 746 ± 182 
Propagated  9 33.0 ± 13.8* 794 ± 215 1079 ± 395* 
Table 3: Extracellular basal levels (mean ± SEM) of interictal extracellular 
glutamate, glutamine, and GABA in patients with medication-refractory epilepsy on 
full AED dosage in the hippocampus and cortex. * P < 0.05 compared to non-
epileptic sites after Bonferroni correction. 
 
A. Glutamate 
A.1. Cortex 
In the cortex basal extracellular glutamate levels were low in the non-epileptic 
sites (mean ± SEM, 2.6 ± 0.3 µM). Glutamate levels were higher in all of the other sites: 
17.3 ± 5.1 µM in epileptogenic, 25.8 ± 4.0 µM in propagated, 43.9 ± 9.9 µM in non-
localized, and 46.9 ± 9.0 µM in lesion sites. The effect of site on glutamate concentration 
was significant in the cortex (F [4, 33] = 26.18, p < 0.0001).  Compared to non-epileptic 
sites, the elevation was significant in epileptogenic (t [33] = 4.40, p = 0.0010), 
propagated (t [33] = 8.10, p < 0.0001), non-localized (t [33] = 7.58, p < 0.0001), and 
lesion sites (t [33] = 8.26, p < 0.0001). No other differences among sites in the cortex 
were significant (adjusted p > 0.05) [FIGURE 4]. 
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A.2. Hippocampus 
In the hippocampus basal glutamate was similarly low in non-epileptic sites (2.8 ± 
0.5 µM) and were comparable to the non-epileptic cortical sites (2.6 ± 0.3 µM). 
Glutamate concentrations were higher in the epileptogenic (10.3 ± 1.9 µM) and 
propagated (33.0 ± 13.8 µM) hippocampal sites. As in the cortex, the effect of site on 
glutamate concentration was significant in the hippocampus (F [2, 3] = 21.70, p = 0.016). 
Compared to non-epileptic sites, the elevation was significant in epileptogenic (t [3] = 
4.38, p = 0.044) and propagated sites (t [3] = 6.42, p = 0.016). There was a non-
significant trend toward higher glutamate in propagated compared to epileptogenic sites 
(p = 0.081). There were no significant differences between the cortex and hippocampus 
among sites of similar epileptogenicity [FIGURE 4]. 
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Figure 4: Basal extracellular glutamate in the cortex and hippocampus. Cortex: non-
epileptic, n = 29 sites; epileptogenic, n = 9; propagated, n = 33; non-localized, n = 21; 
and lesion, n = 15. Hippocampus: non-epileptic, n = 17; epileptogenic, n = 21; and 
propagated, n = 8. In the cortex glutamate levels in the epileptogenic (p = 0.0010), 
propagated (p < 0.0001), non-localizable (p < 0.0001), and lesion (p < 0.0001) sites were 
significantly higher than in the non-epileptic sites. In the hippocampus glutamate was 
significantly elevated in the epileptogenic (p = 0.044) and propagated (p = 0.016) sites 
compared to non-epileptic sites. There were no significant differences between the cortex 
and hippocampus among sites of similar epileptogenicity. Abbreviations: non-epileptic 
(Non-Epi), epileptic (Epi), propagated (Prop), non-localized (Non-Loc), * P < 0.05, ** P 
< 0.005, and *** P < 0.0005. 
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B. Glutamine 
B.1. Cortex 
In the cortex glutamine levels were 721 ± 124 µM in non-epileptic, 818 ± 152 µM 
in epileptogenic, 669 ± 108 µM in propagated, 801 ± 187 µM in non-localized, and 1181 
± 176 µM in lesion sites. There were no significant differences among any of the 
examined sites in the cortex (F [4, 33] = 2.07, p = 0.11) [FIGURE 5]. 
B.2. Hippocampus 
In the hippocampus glutamine was 482 ± 55 µM in non-epileptic, 557 ± 75 µM in 
epileptogenic, and 794 ± 215 µM in propagated sites. Levels of glutamine in the 
hippocampus were also not significantly different between sites (F [2, 2] = 3.99, p = 0.20) 
[FIGURE 5]. In addition, there were also no significant differences between the cortex and 
hippocampus among sites of similar epileptogenicity (p > 0.05). 
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Figure 5: Basal extracellular glutamine in the cortex and hippocampus. Cortex: non-
epileptic, n = 28 sites; epileptogenic, n = 9; propagated, n = 33; non-localized, n = 21; 
and lesion, n = 15. Hippocampus: non-epileptic, n = 14; epileptogenic, n = 19; and 
propagated, n = 8. There were no significant differences in glutamine among sites in the 
cortex or hippocampus. There were also no significant differences between the cortex and 
hippocampus among sites of similar epileptogenicity. Abbreviations: non-epileptic (Non-
Epi), epileptic (Epi), propagated (Prop), and non-localized (Non-Loc).  
 
C. GABA 
C.1. Cortex 
In the cortex GABA levels were lowest in the non-epileptic sites (265 ± 62 nM), 
compared to 921 ± 456 nM in epileptogenic, 1503 ± 273 nM in propagated, 720 ± 172 
nM in non-localized, and 827 ± 183 nM in lesion sites. There were significant differences 
in GABA concentrations among cortical sites (F [4, 31] = 5.03, p = 0.0030).  GABA was 
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significantly higher in propagated (t [31] = 4.13, p = 0.0022) and lesion sites (t [31] = 
3.38, p = 0.016) than in non-epileptic sites. There was no significant difference between 
epileptogenic and non-epileptic sites (t [31] = 2.08, p = 0.25), nor were there any other 
significant differences in GABA concentrations between cortical sites [FIGURE 6]. 
 
C.2. Hippocampus 
In the hippocampus GABA was also lowest in non-epileptic sites (391 ± 169 nM) 
compared to 746 ± 182 nM in epileptogenic and 1079 ± 395 nM in propagated sites. 
There were significant differences among hippocampal sites (F [2, 43] = 4.05, p = 0.025). 
GABA was significantly elevated in propagated compared to non-epileptic sites (t [43] = 
2.73, p = 0.024). There were no significant differences between epileptogenic and non-
epileptic sites (t [43] = 1.83, p = 0.17) or between epileptogenic and propagated sites (t 
[43] = 1.47, p =0.32) [FIGURE 6]. 
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Figure 6: Basal extracellular GABA in the cortex and hippocampus. Cortex: non-
epileptic, n = 27 sites; epileptogenic, n = 9; propagated, n = 31; non-localized, n = 21; 
and lesion, n = 14. Hippocampus: non-epileptic, n = 17; epileptogenic, n = 22; and 
propagated, n = 7. In the cortex GABA was significantly elevated in propagated (p = 
0.0022) and lesion (p = 0.016) compared to non-epileptic sites. In the hippocampus 
GABA was significantly elevated in propagated compared to non-epileptic sites (p = 
0.024) There were no significant differences among sites of similar epileptogenicity 
between the cortex and hippocampus. Abbreviations: non-epileptic (Non-Epi), epileptic 
(Epi), propagated (Prop), non-localized (Non-Loc), * P < 0.05, and **P < 0.005. 
 
D. Cortex and Hippocampus Combined 
There were no significant differences in glutamate, glutamine, or GABA between 
the hippocampus and cortex within non-epileptic, epileptogenic, and propagated sites (all 
p > 0.05). Because of the similarity in neurochemical levels between the cortex and 
hippocampus, hippocampal and cortical sites were combined within non-epileptic, 
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epileptogenic, and propagated groups to increase the power of this and the medication 
taper analysis. Concentrations in glutamate, glutamine, and GABA were then compared 
among these combined groups. For glutamate the combined means were 2.7 ± 0.3 µM in 
non-epileptic, 12.4 ± 2.0 µM in epileptogenic, and 27.2 ± 4.1 µM in propagated sites. 
Epileptogenic (t [44] = 7.01, p <0.0001) and propagated sites (t [44] = 11.82, p < 0.0001) 
had significantly higher glutamate concentrations than non-epileptic sites. Propagated 
sites had significantly higher glutamate than epileptogenic sites (t [44] = 4.50, p = 
0.0001). While no significant differences were detected in the earlier comparisons 
between epileptogenic and propagated probes in the cortex and hippocampus, the larger 
sample size afforded by combining hippocampal and cortical sites was now powered to 
detect this significant difference [FIGURE 7A]. 
For glutamine the combined means were 641 ± 86 µM in non-epileptic, 641 ± 73 
µM in epileptogenic, and 693 ± 96 µM in propagated sites. There were no significant 
differences in glutamine between non-epileptic, epileptogenic, and propagated sites (F 
[43, 2] = 1.39, p = 0.26), reflecting the findings of the separate hippocampal and cortical 
analyses [FIGURE 7B]. 
For GABA the combined means were 313 ± 75 nM in non-epileptic, 797 ± 181 
nM in epileptogenic, and 1425 ± 234 nM in propagated sites. Epileptogenic (t [42] = 
3.03, p = 0.011) and propagated (t [42] = 5.47, p < 0.0001) sites had significantly higher 
GABA concentrations than non-epileptic sites. GABA in propagated sites was also 
significantly higher than in epileptogenic sites (t [42] = 5.47, p = 0.028). The increased 
power from combining hippocampal and cortical sites enabled detection of significant 
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differences between epileptogenic and non-epileptic sites and between propagated and 
epileptogenic sites [FIGURE 7C]. 
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Figure 7: Basal extracellular glutamate, glutamine, and GABA after combining 
cortical and hippocampal sites. A) Glutamate in the epileptogenic (n = 30) and 
propagated (n = 41) sites was significantly higher than in non-epileptic (n = 46) sites 
(both p < 0.0001). Additionally, glutamate in the propagated sites was significantly 
higher than in epileptogenic sites (p = 0.0001). B) There were no significant differences 
in glutamine across sites (non-epileptic, n = 42; epileptogenic, n = 28; and propagated, n 
= 41; p > 0.05). C) GABA was significantly higher in epileptogenic (n = 31, p = 0.011) 
and propagated (n = 38, p < 0.0001) sites compared to non-epileptic sites (n = 44). 
GABA was also higher in propagated than epileptogenic sites (p = 0.028). * p < 0.05, *** 
p < 0.0005. 
 
III. Antiepileptic Medication Taper 
For this analysis, only patients who had two basal microdialysis studies (on initial 
dose of AED meds, "AED on" and on tapered dose, "AED tapered", as defined in the 
methods) were included.  Data from 38 patients (18 males and 20 females) of age 32.2 ± 
9.6 years (mean ± SD) studied between 2002 and 2008 were analyzed. This represented 
data from 40 intracranial studies (subjects) involving 76 microdialysis probes in 73 
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microdialysis sites (Figure 8). Two patients were studied twice, and these repeated 
intracranial studies were treated as separate subjects (n = 40), as in the above basal 
comparison. Two hippocampi contained two probes each and one dysplasia contained 
two probes; their values were averaged for each structure. Seventeen probes were 
excluded due to: missing microdialysis data (n = 4), too few probes for group analysis (n 
= 3, all hippocampi in non-localized patients), unclear probe location (n = 2), excluded 
location (n = 7: basal ganglia, thalamus, tumor, ventricle, internal capsule, and corpus 
callosum), and seizure activity during collection (n = 1).  The basal collections after AED 
taper were obtained 4.4 ± 1.8 days (mean ± SD) after the basal collection on initial dose 
of AEDs (AED On). The AED condition was defined as tapered (AED Tap) if at least 
one medication was reduced by 50% from the full medication dose within 24 hours of 
sample collection. AEDs administered included acetazolamide (ACTZ) carbamazepine 
(CBZ), felbamate (FBM), gabapentin (GBP), lamotrigine (LTG), levetiracetam (LEV), 
oxcarbazepine (OXC), phenobarbital (PB), phenytoin (PHT), topiramate (TPM), 
valproate (VPA), and zonisamide (ZNS). Six subjects were on AED monotherapy, 21 
were on 2 AEDs, 12 were on 3 AEDs, and 1 was on 4 AEDs. 
In an earlier analysis (see Results II.D) we found no significant differences in 
glutamate, glutamine or GABA between the cortex and hippocampus within the non-
epileptic, epileptogenic or propagated sites.  Therefore, to increase the statistical power, 
data from the cortical and hippocampal sites for each category (i.e. non-epileptic, 
epileptogenic, or propagated) were combined for glutamate, glutamine and GABA.  
Thus, there were 13 non-epileptic, 9 epileptogenic and 27 propagated combined sites.  
Non-localized and lesion sites were exclusively located in the cortex: 15 non-localized 
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sites located in 8 subjects and 9 lesion sites (10 probes) were included. The lesion sites 
comprised 2 cortical tubers, 3 dysplasias (containing 2 averaged probes), 1 CSF cleft, 1 
encephalomalacia, and 2 heterotopias.  
The mean pre-taper level, post-taper level, and differences in glutamate, 
glutamine, and GABA are reported below (Table 4). In contrast to the previous single 
basal analysis, the within-subject effect on neurochemical concentration was non-
significant and, therefore, the nested statistical model was abandoned for the medication 
taper analysis. 
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Figure 8: Flow-chart of microdialysis probe inclusion and classification within the 
hippocampus and cortex for the medication taper analysis.* The number of subjects 
is greater than the number of patients, because several patients underwent multiple 
intracranial studies. ** Data from probes located in the same structure (hippocampus or 
lesion) were averaged to represent a single site. 
 
Table 4A. 
Probe Sites # Sites 
GLU On 
(µM) 
GLU Tap 
(µM) 
Δ GLU  
(µM) 
Non-epileptic 13 3.6 ± 0.7 3.6 ± 1.4 0 ± 1.4 
Epileptogenic 9 16.1 ± 3.2 28.3 ± 9.7 +12.2 ± 10.3 
Propagated 27 30.4 ± 4.7 32.1 ± 6.3 +1.6 ± 6.8 
Non-localized 15 57.5 ± 12.1 35.4 ± 6.9 -22.1 ± 10.5 
Lesion 9 63.0 ± 11.1 68.8 ± 19.7 +5.8 ± 22.1 
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Table 4B. 
Probe Sites # Sites 
GLN On 
(µM) 
GLN Tap 
(µM) 
Δ GLN 
(µM) 
Non-epileptic 13 753 ± 214 513 ± 129 -240 ± 107 
Epileptogenic 9 582 ± 122 543 ± 71 -39 ± 130 
Propagated 27 730 ± 132 668 ± 129 -62 ± 43 
Non-localized 15 980 ± 248 743 ± 98 -237 ± 207 
Lesion 9 1299 ± 202 522 ± 99 -776 ± 208* 
 
Table 4C. 
Probe Sites # Sites 
GABA On 
(nM) 
GABA Tap 
(nM) 
Δ GABA 
(nM) 
Non-epileptic  11 221 ± 70 133 ± 43 -88 ± 63 
Epileptogenic  8 1229 ± 445 780 ± 334 -450 ± 544 
Propagated  21 1438 ± 296 1506 ± 482 +68 ± 326 
Non-localized 15 894 ± 224 330 ± 59 -563 ± 226* 
Lesion 7 1170 ± 249 845 ± 310 -325 ± 307 
 
Table 4: Basal levels of interictal (A) glutamate, (B) glutamine, and (C) GABA on 
full AED dose (On) and after the medications are tapered (Tap) with the change in 
concentration after taper (Δ). * P < 0.05, Bonferroni-adjusted. 
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A. Glutamate 
 The effect of AED taper on glutamate levels was examined across all sites (non-
epileptic, epileptogenic, propagated, non-localized, and lesion). The overall taper effect 
on glutamate across all sites showed a non-significant trend toward glutamate decrease (t 
[72] = -1.66, p = 0.1017). There were no significant changes in glutamate with taper 
(adjusted p > 0.05) in any of the five sites (all Bonferroni adjusted p > 0.05). There was a 
non-significant trend toward glutamate decrease in non-localized sites (-22.1 ± 10.5 µM, t 
[14] = -2.68, p = 0.090). There were no significant differences in the magnitude of 
glutamate change between sites (F [4, 72] = 1.43, p = 0.2317). 
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Figure 9: Effect of AED taper on basal extracellular glutamate levels by site. Non-
epileptic, n = 13 sites; epileptogenic, n = 9; propagated, n = 27; non-localized, n = 15; 
and lesion, n = 9. There were no significant changes (p > 0.05) in glutamate with taper in 
any of the 5 sites (all p>0.05). There was a non-significant trend toward decreased 
glutamate in non-localized sites (p = 0.09). Data are presented as mean ± SEM. 
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B. Glutamine 
 When site was not considered, glutamine demonstrated a significant decrease with 
AED taper (t [72] = -3.40, p = 0.0011). When examined by site, there was a significant 
decrease in glutamine in the lesion sites only (-776 ± 208 µM, t [8] = -4.54, p = 0.0095). 
No other sites exhibited significant changes in glutamine (p > 0.05). 
 There were significant differences in the magnitude of glutamine change between 
sites (F [4, 72] = 4.50, p = 0.0028). Post-hoc analysis on the magnitude of glutamine 
change demonstrated that the glutamine decrease in lesions was significantly greater than 
in the other four sites, but no distinction could be made between non-epileptic, 
epileptogenic, propagated, or non-localized sites. 
Figure 10: Effect of AED taper on basal extracellular glutamine levels by site. Non-
epileptic, n = 13 sites; epileptogenic, n = 9; propagated, n = 27; non-localized, n = 15; 
and lesion, n = 9. AED taper resulted in significant glutamine decrease only in the lesions 
sites (*p = 0.0095). Data are presented as mean ± SEM. 
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C. GABA 
 When site was not considered, GABA decreased significantly overall with AED 
taper (t [61] = -4.65, p < 0.0001). Examined by site, AED taper was associated with a 
significant decrease in GABA in the non-localized sites only (-563 ± 226 nM, t [14] = - 
3.61, p = 0.014). There were no significant changes in GABA in non-epileptic, 
epileptogenic, propagated and lesion sites (adjusted p > 0.05). 
 
Figure 11: Effect of AED taper on basal extracellular GABA levels by site. Non-
epileptic, n = 12 sites; epileptogenic, n = 9; propagated, n = 24; non-localized, n = 15; 
and lesion, n = 8. AED taper was associated with a significant decrease in GABA only in 
the non-localized sites (*p = 0.014). Data are presented as mean ± SEM. 
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Discussion 
 This study has built upon the previous work of Cavus and colleagues (49) that 
examined the basal interictal extracellular concentrations of glutamate and glutamine in 
the epileptogenic and non-epileptic hippocampus and cortex of patients with medically-
refractory epilepsy. Here, in a much larger sample size involving a total of 89 subjects, 
including the original 38 patients from Cavus et al.’s 2005 publication (49), we report the 
interictal basal levels of glutamate, glutamine and GABA not only in the epileptogenic 
and non-epileptic human hippocampus and cortex, but also in seizure propagation sites, 
MRI-identified lesions, and patients in whom the seizure onset site could not be localized 
(non-localized). In addition, we examined the effect of AED taper on the interictal 
glutamate, glutamine and GABA levels in a subset of these subjects. To our knowledge, 
this is the first study reporting on such work in such an extensive number of subjects with 
refractory epilepsy.  
I. Basal Glutamate, Glutamine, and GABA in the Cortex and 
Hippocampus 
Glutamate 
The interictal basal glutamate levels in the non-epileptic hippocampus and cortex 
were low and remarkably similar (hippocampus, 2.8 ± 0.5 µM vs. cortex, 2.6 ± 0.3 µM).  
These values were also similar to those previously reported in the non-epileptogenic 
cortex and hippocampus of a subset of our subjects by Cavus et al. (49, 50) and in the 
striatum of normal freely-moving rats (3.0 ± 0.6 µM) (206). Although the invasiveness of 
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the microdialysis studies precludes obtaining data from control human subjects, the 
findings in non-epileptic brain sites presumably closely approximate normal brain tissue. 
The consistency of our findings in non-epileptic sites with previously reported results in 
both humans and animals demonstrates that extracellular glutamate is very tightly 
regulated under normal conditions (86, 88, 207). These findings further confirm the 
consistency of microdialysis measurements under chronic conditions in human subjects.  
In a previous study in 38 of our subjects, Cavus and colleagues found that the 
basal concentration of glutamate was significantly elevated in the epileptogenic 
hippocampus compared to the non-epileptic hippocampus, while the elevation in the 
epileptogenic cortex did not reach significance (49). Here, we confirm higher interictal 
glutamate levels in the epileptogenic hippocampus (10.3 ± 1.9 µM) compared to the non-
epileptogenic hippocampus (p = 0.044). Furthermore, with the advantage of adding 
additional subjects (since 2004) to the original 38, we find that the glutamate in the 
epileptogenic cortex (17.3 ± 5.1 µM) is now significantly higher than in the non-epileptic 
cortex (p = 0.0010). There were no regional differences (i.e. hippocampus vs. cortex) in 
glutamate levels in the non-epileptic, epileptogenic, or propagated sites. Although 
hippocampal and neocortical epilepsies have different pathologies (208) and biogenic 
amine profiles (209), the levels of glutamate, glutamine, and GABA in these regions were 
comparable, which suggests that metabolic abnormalities associated with epilepsy have a 
similar effect on extracellular neurochemicals. 
 Remarkably, we found that extracellular glutamate was significantly elevated in 
all other examined sites: in both the propagated cortex (25.8 ± 4.0 µM) and hippocampus 
(33.0 ± 13.8) and in non-localized (43.9 ± 9.9 µM) and lesion (46.9 ± 9.0 µM) sites in the 
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cortex. In fact, the interictal elevation of glutamate in the propagated hippocampal and 
cortical sites was even significantly higher than in the epileptogenic sites (p = 0.0001). 
This was surprising because, although propagated sites are exposed to greater seizure 
activity than non-epileptic sites, they are located in comparably normal brain tissue not 
known to be affected by the synaptic reorganization and gliosis seen in epileptogenic and 
lesion sites. However, evidence from neuroimaging studies in epilepsy patients also 
indicates that abnormalities extend beyond the sites of seizure origin (210). In patients 
with MTS, bilateral cortical thinning is present on MRI (211, 212), and PET 
abnormalities project beyond hippocampal (213) and neocortical (214) sites of seizure 
origin along established intra-cortical connections. Our findings of elevated interictal 
glutamate in sites outside of the seizure origin are consistent with these findings, and 
suggest that, in medication-refractory epilepsy patients, there is a widespread impairment 
in glutamate homeostasis. This elevation in the extracellular glutamate could be a result 
of increased neuronal and glial release due to impaired metabolism, inadequate glutamate 
reuptake following repeated seizures, or a combination of both (70, 73, 74, 79, 215).  It is 
possible that this glutamate elevation may enhance seizure propagation, as increased 
neuronal activity can amplify astrocytic glutamate release (82), and the release of 
astrocytic glutamate could initiate neuronal depolarization and glutamate release distant 
from the seizure focus (83). 
These findings of widespread glutamate elevation may have implications for the 
outcomes of surgical treatment of these patients. It is unknown if high extracellular 
glutamate in propagated sites, which are usually not resected with the focus (20), predicts 
poor surgical outcome.  However, the presence of extensive PET abnormalities before 
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surgery has been associated with decreased seizure freedom following resection (203). 
Alternatively, PET abnormalities in seizure projection sites may improve after resective 
surgery (216, 217), and it is possible that the elevated glutamate in propagated sites may 
decrease following resection of the epileptogenic focus. 
Patients are classified as non-localized if their intracranial EEG study fails to 
consistently identify a seizure focus. This often occurs because seizures originate from 
multiple foci, although, in some cases, there may be a single seizure focus that was 
inadequately covered by the electrode array. The presence of elevated glutamate in 
multiple sites in non-localized patients could be consistent with the presence of global 
dysfunction in the regulation of glutamate and multifocal seizure onset. Although not 
completely analogous to microdialysis conducted in non-localized patients, MRS studies 
on patients with generalized epilepsy demonstrate elevation of glutamate-glutamine 
(GLX) in the occipital (218) and frontal lobes (219), suggesting a global dysfunction. 
 Glutamate was elevated in lesions, which included heterotopias, dysplasias, 
tuberous sclerosis, and encephalomalacias. Because of the limited sample sizes, lesion 
sites have been previously excluded from other microdialysis reports (35, 49, 50).  
However, our findings are consistent with the limited human and animal data on 
glutamate changes in tumors and lesions. While non-neoplastic lesions have not 
previously been studied by microdialysis in humans, microdialysis conducted in patients 
with high-grade astrocytoma has identified elevated glutamate both within tumors and in 
the adjacent (radiographically normal) brain (220). Although not examined here, we have 
observed similar glutamate elevations both within neoplasms and in the surrounding 
brain (I. Cavus, unpublished observations). MRS studies of malformations of cortical 
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development in patients with refractory epilepsy have identified elevated GLX within the 
lesion sites (221). Microdialysis in a mouse tuberous sclerosis model identified elevated 
extracellular hippocampal glutamate, which was associated with neuronal death (222), 
suggesting that some developmental abnormalities may be associated with widespread 
dysfunction in glutamate homeostasis and that this elevation in glutamate may be 
neurotoxic. Rats in a cortical dysplasia injury model are susceptible to excitability when 
glutamate transport is blocked (223), which may elucidate the mechanisms underlying the 
epileptogenic properties of lesions in humans. This widespread elevation of glutamate in 
the propagated, non-localized, and lesion sites suggests that the dysregulation of 
glutamate homeostasis in the epileptic brain is much more widespread then originally 
anticipated. 
Multiple microdialysis studies have identified elevations in extracellular 
glutamate in medically-refractory epilepsy patients both during seizures (43, 47, 48, 113) 
and in the interictal period (35, 49, 50, 52). Although the origin and significance of this 
glutamate in epileptic patients is not completely known (73), elevated glutamate has been 
shown to be neurotoxic in cell culture (95), and chronic exposure is associated with 
neurodegeneration in rats (98) and hippocampal atrophy in humans (50). Although a rise 
in glutamate alone does not appear to induce seizures, it lowers the seizure threshold and 
enhances epileptogenesis (87). Consequently, extracellular glutamate is a promising 
target for future epilepsy pharmacotherapy (204). 
GABA 
 The interictal extracellular levels of GABA in the non-epileptic hippocampus and 
cortex were comparable (hippocampus, 391 ± 169 nM vs. cortex, 265 ± 62 nM, p > 0.05) 
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and were remarkably similar to those obtained in the striatum of normal rats (270 ± 40 
nM) (224). Surprisingly, we found that compared to the non-epileptic sites, GABA was 
significantly elevated in the propagated sites in both the hippocampus (1079 ± 395 nM; p 
= 0.024) and in the cortex (1503 ± 273 nM; p = 0.0022), as well as in the cortical lesions 
(827 ± 183 nM; P = 0.016). Although the metabolic substrates underlying extracellular 
GABA elevation in the hippocampus and cortex may differ, (51), there were no 
differences in extracellular GABA concentration between the hippocampus and cortex 
within non-epileptic, epileptogenic, and propagated sites. When the hippocampal and 
cortical sites were combined, it became apparent that GABA was also significantly 
elevated in epileptogenic sites compared to non-epileptic sites (p = 0.011) and, 
furthermore, that the GABA in propagated sites was higher than in epileptogenic sites (p 
= 0.028). These significant and novel differences were only appreciated after combining 
the hippocampal and cortical probes, illustrating the necessity of larger sample sizes to 
appreciate extracellular neurochemical variations. 
The elevation of extracellular GABA within lesions is a novel finding. Although 
the specific mechanism of this elevation is unclear, there is evidence from tissue studies 
of impaired regulation of GABA in lesions. In resected dysplasias GABAergic neuron 
and GABA transporter organization have been reported to be abnormal (225), and 
decreased inhibitory postsynaptic potentials, GABA clearance and transporter expression 
have been identified (226).  
 The similar distributions of elevated extracellular GABA and glutamate suggest 
that metabolic abnormalities extend beyond seizure onset sites and lead to increased 
concentrations of both neurotransmitters. It is unknown if increased GABA is due to 
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chronic seizure activity, follows seizure propagation tracts, reflects interictal impairment 
in GABA regulation, or is an effect of medications. The medication taper analysis (see 
below), demonstrated an overall GABA reduction in response to AED withdrawal, which 
suggests that elevated GABA may be partially related to AED administration and that, if 
present, this AED-related amplification of GABA may be greater in abnormal brain 
regions (i.e. outside of non-epileptic sites). Extracellular GABA increases with seizures 
in patients with refractory epilepsy and may serve to limit seizure activity (47, 48). 
Indeed, there is evidence of increased interictal inhibitory activity in epileptogenic 
regions in humans (227) that may be related to the elevated GABA we find in those sites. 
There is also substantial evidence from sclerotic human hippocampi and animal models 
of epilepsy of impaired GABA transport in epileptogenic states (113, 114, 228).  
Alternately, the elevated extracellular GABA may enhance rather than mitigate 
epileptogenesis. Chronic seizure activity has been reported to increase the reversal 
potential of GABA, rendering GABA paradoxically excitatory (116). This excitatory 
property of GABA is hypothesized to contribute to interictal electrical activity (229) and 
the development of epileptogenic foci in human MTLE (230). It is possible that 
excitatory or inhibitory properties of GABA may predominate in different brain regions 
within the same patient. For example, GABA elevation is associated with improved 
mitochondrial energy metabolism in non-epileptic hippocampi but with worsened energy 
metabolism in epileptogenic hippocampi (51), so increased GABA in epileptogenic 
hippocampi may be pathologic and excitatory, while GABA in non-epileptic or 
propagated sites may be a normal response to chronic excitation that counteracts seizure 
spread. Nevertheless, the inhibitory properties of GABA may be attenuated in patients 
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with epilepsy, as there is evidence that GABA receptors are maximally activated but 
functionally impaired in the presence of chronic seizures (231). Also, extracellular basal 
GABA concentrations may not accurately reflect the GABAergic response to seizure 
initiation, which is diminished in epileptogenic compared to non-epileptic hippocampi 
(47). 
Glutamine 
 Glutamine levels in the non-epileptic hippocampus and cortex were similar 
(hippocampus, 482 ± 55 µM vs. cortex 721 ± 124 µM, p > 0.05). These levels were 
higher than levels found in the normal rat hippocampus (193 ± 10.9 µM) (232). There 
were no significant differences in basal extracellular glutamine concentrations between 
any of the sites and regions examined, regardless of their involvement in seizure activity. 
Although glutamine does not, itself, function as a neurotransmitter, it is a critical 
component in the metabolism of both glutamate and GABA (88, 100). A low ratio of 
glutamine to glutamate (i.e. high glutamate and low glutamine), as measured by 
microdialysis, has been associated with poor outcome in children with traumatic brain 
injury (233), although its prognostic significance in epilepsy is unknown. These 
microdialysis findings of low glutamine in the setting of high glutamate support evidence 
of impaired glutamate-glutamine cycling, which could result from a combination of 
impaired glutamate uptake and decreased glutamine synthetase function in glia. Evidence 
of decreased glial glutamate transport (89, 234), glutamine synthetase expression (102, 
235), and impaired glutamate-glutamine cycling (49, 101) have been identified in the 
human epileptogenic hippocampus Reduced glutamine availability or glutaminase 
function could also impair inhibitory GABAergic neurotransmission (103, 236). Our 
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results suggest that despite the reported decrease in glutamine synthetase in the 
epileptogenic hippocampus, extracellular glutamine levels are regulated at a constant 
level across all regions regardless of their degree of involvement in seizure activity. 
II. Antiepileptic Medication Taper 
Although they have been examined in animal models, the effects of AEDs on 
extracellular glutamate, glutamine, and GABA have not previously been studied by 
microdialysis in humans. Several microdialysis studies have been conducted on basal 
extracellular neurochemical levels at a single point in time (35, 49-52), often when 
patients are on their full dose of AEDs, but the extent to which AEDs may contribute to 
these levels has not been specifically examined. Since most AEDs exert their effects by 
decreasing neuronal excitation, which is primarily glutamatergic, or enhancing inhibition, 
which is primarily GABAergic, medication withdrawal might be expected to influence 
these extracellular neurotransmitter levels. Many AEDs have multiple mechanisms of 
action, and their effects may be astrocytic as well as neuronal. For example, valproate, 
gabapentin, and phenytoin have been shown to decrease calcium-mediated signaling 
between astrocytes, which may enhance their antiepileptic properties in neurons by 
decreasing the astrocytic contribution to extracellular glutamate (83). Due to these 
complex interactions, the effect of AEDs on glutamate, glutamine, and GABA in the 
human brain may be more complicated than that predicted by individual drug 
mechanisms or their effects in animal models. Because the nature of this study renders 
correlation of neurochemical concentrations with individual drugs and their doses 
impossible, the taper period should be viewed as a state of increased susceptibility to 
seizures rather than the result of specific medication changes, as has been done in several 
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studies on the electrographic effects of AED taper (33, 34, 36), rather than the result of 
specific medication changes. 
 
Glutamate: 
 Following AED taper, glutamate did not change significantly in any of the 
examined sites (non-epileptic, epileptogenic, propagated, or lesions). There was a trend to 
decrease only in the non-localized sites (-22.1 ± 10.5 µM, p = 0.09). The failure to detect 
any significant changes in the extracellular glutamate with AED taper is consistent with 
animal studies on many AEDs, including CBZ (135), LEV (146), LTG (64), PHT (67, 
135), TPM (148), VPA (S. Ahmad et al., 2005b; (67), and ZNS (137), in which no 
change in basal extracellular glutamate was observed after AED administration. MRS 
data in humans, though predominantly measuring intracellular concentrations, also 
suggest that AEDs may not significantly reduce glutamate in patients with medication-
refractory epilepsy (121), the patient subtype studied by microdialysis. Many of the 
current AEDs may not target mechanisms that regulate the basal extracellular glutamate. 
Because some AEDs, especially sodium-channel blockers, are known to be use-
dependent (130), their effects on basal glutamate levels, obtained during periods of 
relative inactivity, may be minimal. This property may also explain why the same 
medication may affect basal (Table 2) and evoked (Table 1) neurotransmitters differently 
in animal microdialysis studies. 
 Another possibility, especially in a patient population that is defined by resistance 
to multiple AEDs, is that changes in the drug targets or reduced drug accumulation in the 
extracellular space due to transporter-mediated efflux by P-gp or MRPs (237) prevent 
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these medications from exerting their effects on extracellular glutamate. Increased efflux 
transporter expression is seen in epileptogenic tissue (178, 179, 181) and is associated 
with chronic seizures in humans and animal models (187-189). Still, the effect of efflux 
transporters on AED function in humans is unknown. If efflux transporters are clinically 
significant in humans, they would be expected to be associated with resistance to more 
than one AED (202). The association of elevated extracellular glutamate with increased 
efflux transporter expression (190, 191) may directly link the microdialysis glutamate 
data with medication response. If high glutamate at baseline were associated with poor 
drug influx, then the medication effect should be attenuated in areas where glutamate is 
already high. In addition, cortical dysplasias and tubers are associated with increased 
drug efflux transporter expression at baseline (179-181). 
Nonetheless, glutamate did decrease, albeit non-significantly, in non-localized 
patient sites. The decrease of glutamate in these sites likely heavily influences the trend 
in glutamate decrease (p = 0.102) observed when all sites are considered together. Since 
these patients are defined by the inability to localize their seizure onset to a single site, 
often due to multifocality, this may represent a pathology that is distinct from that of 
single-onset epilepsy. Since medication taper is associated with decreased Teager energy 
(36) and Teager energy is positively correlated with extracellular glutamate levels (51), it 
would follow that medication taper is associated with decreased extracellular glutamate. 
One plausible hypothesis is that this is related to increased feedback inhibition on 
extracellular glutamate release, a process that might be modulated by presynaptic 
metabotropic glutamate receptors (238). However, since these non-localized sites 
represent a heterogeneous group, ranging from localization-related epilepsy with 
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undetectable foci to true generalized seizure onset, any conclusions from these results 
should be approached with caution. Also, the failure to detect significant changes in other 
sites could be a function of the relatively small sample sizes examined. 
Glutamine:  
Following AED taper glutamine did not significantly change in non-epileptic, 
epileptogenic, propagated, or non-localized sites but decreased significantly in lesion 
sites (-776 ± 208 µM, p = 0.0095). These results may be due to differences in glutamate-
glutamine cycling within lesions, although there was no accompanying significant change 
in glutamate within lesions. The glutamine decrease in lesions may indicate a different 
metabolic pattern from non-lesional cortex. In a C-13 labeling study comparing human 
tissue from MTS and dysplasias, both tissues exhibited evidence of decreased glutamate 
uptake, although glutamine synthetase was intact in dysplasias and impaired in MTS, 
while neuronal mitochondrial function was impaired in dysplasias but relatively 
unaffected in MTS (239). It is important to emphasize that the lesions considered in our 
microdialysis study were comprised of multiple pathologies, including heterotopias, 
tubers, and encephalomalacias in addition to dysplasias. A possible explanation for 
decreased extracellular glutamine in the setting of unchanged extracellular glutamate is 
that more glutamate is produced during the pro-epileptogenic state of AED taper, but it is 
located intracellularly or in synapses and is consequently not detectable by microdialysis 
(73). This would be consistent with the theory that pro-epileptogenic conditions favor the 
conversion of excess glutamine to glutamate rather than GABA (105). Another 
consideration is that glutamine levels are in balance with ammonia and related to nitrogen 
metabolism. For example, valproate has been shown to increase brain glutamine by 
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inducing hyperammonemia (165). This is a less likely explanation in the present study, 
because only one of nine lesion sites underwent a taper in valproate (although, this was 
accompanied by a reduction of glutamine from 1850 to 525 µM). Interestingly, since 
several AEDs incidentally inhibit glutamine synthetase, glutamine might actually be 
expected to increase after drug withdrawal (166).    
 
GABA: 
 Following AED taper GABA decreased significantly in non-localized sites (-563 
± 226 nM, p = 0.014), similar to glutamine, but it did not significantly change in non-
epileptic, epileptogenic, or propagated sites. There was an overall significant decrease in 
GABA when all sites were examined together (p < 0.00001), and the degree of decrease 
in GABA concentration was not significantly different between sites when they were 
examined separately. Although it was not possible to examine the change in GABA by 
individual drugs or drug classes due to the small number of patients in whom only one 
AED was tapered, these results suggest that many of these AEDs enhanced extracellular 
GABA. This effect has been demonstrated on whole brain GABA for some AEDs in 
patients with epilepsy (123-125) and in healthy subjects (126).  Increased basal GABA 
has been also demonstrated in animal microdialysis studies after administration of AEDs, 
such as valproate (67, 131, 139), vigabatrin (149), and tiagabine (147). In this study, no 
patients in the current microdialysis study were on vigabatrin or tiagabine, but valproate 
was a constituent of many therapeutic regimens. The prominence of this effect in non-
localized patients, as for glutamate, may be due to the larger sample size of this group 
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(n=15 sites) or may indicate a different metabolic profile from true localization-related 
epilepsy. 
Medication taper is clinically associated with increased seizure frequency, which 
may be related to decreased neuronal inhibition. Increased whole-brain GABA identified 
on MRS is associated with improved seizure control (107), although patients with 
medication-refractory epilepsy are more likely to have subnormal GABA levels after 
AED administration (121). Based on our microdialysis results, it is possible that 
extracellular, as well as neuronal, GABA is involved in mitigating epileptogenesis. 
GABA may have effects in regions of different epileptic activity. For example, an AED-
induced increase in extracellular GABA may attenuate seizure spread in propagated 
regions. Although increasing GABAergic tone may enhance seizure control, this effect is 
broadly distributed and contributes to the cognitive impairments seen with GABAergic 
AEDs (240, 241). It is also important to consider that, as discussed previously, increased 
GABA may promote inhibition as well as excitation, depending on its reversal potential 
(115, 116, 229, 230).  
 
III. Limitations and Future Directions 
 While in vivo microdialysis in conscious humans has provided many valuable 
insights into the neurochemical substrates of medication-refractory epilepsy, this 
technique has several inherent limitations. Although these studies involve the largest 
dataset of epilepsy patients studied by microdialysis, the sample sizes involved, 
especially in the medication taper analysis, are still small relative to the number of 
comparisons made. Unfortunately, as intracranial electrographic studies are a significant 
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undertaking and only eight to twelve patients are studied annually at our center, it would 
take many years to accrue a larger number of subjects. All data were collected in subjects 
with medication-refractory epilepsy, since normal controls and patients with drug-
responsive epilepsy would not ethically be candidates for the invasive catheter 
implantation procedure. Consequently, the findings may not be applicable to patients 
with drug-responsive epilepsy, and comparisons can only be made to non-epileptic sites 
in patients with epilepsy rather than normal controls, with the assumption that non-
epileptic sites approximate the conditions in normal brain. Microdialysis probe locations 
are chosen in advance based on clinical suspicion of epileptic activity; therefore, the 
number and types of sites to sample with microdialysis cannot be predetermined or 
controlled. In addition, not all microdialysis probes function after insertion. 
Consequently, some patients have multiple probes and some probe groups are over-
represented, such as cortical seizure propagation sites, while others, such as cortical 
seizure onset sites, are under-represented. These limitations have been considered by 
classifying probe activities according to a consensus of independent epileptologists and 
by adjusting for the within-subject effect on probes in patients with multiple probes. 
Every attempt possible has been in the microdialysis methodology to standardize 
collection conditions between patients. To decrease the variability in neurochemical 
levels based on diurnal variations, sleep, food intake etc, all basal samples were collected 
in the afternoon, at least 4-6 hours after any seizure activity. However, differences in 
clinical conditions, behavioral activity, administered AEDs and other medications (such 
as antibiotics, corticosteroids, and pain relievers), seizure frequency, and other variables 
may also affect neurotransmitter concentration and cannot presently be controlled for. 
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Following several initial measurements and continual random sampling and quality 
control, all probes have been assumed to have the same fractional recovery of 0.8, 
although it is possible that slight differences may exist between probes and could change 
over the sampling period. Although samples have been obtained over a period of ten 
years under different investigators and staff, the procedures for microdialysate collection, 
storage, and analysis have been standardized, and any changes to the protocol have been 
followed by quality analysis to ensure that the results are consistent with those obtained 
by previous methods. 
 As the medication taper analysis was conducted on a subset of patients included 
in the single basal analysis, the sample sizes were even smaller, and many patients were 
on multiple medications. The medication taper was individualized to fit the clinical needs 
of each patient, guided by the need to record an adequate number of seizures for 
electrographic localization. Consequently, it was impossible to discern effects of single 
medications on glutamate, glutamine, and GABA. This is unfortunate, because, while 
these effects have been studied in animal models, these data are not available in humans, 
in whom the drugs may have different effects. Ideally, if data from more patients were 
available, it may become possible to explore the effects of medication classes, if not 
individual AEDs. 
The neurochemicals of interest may also have been subject to a number of 
confounding factors. Non-AED medications known to affect glutamate were also 
adjusted over the taper period. Most patients received prophylactic antibiotics, usually 
cephalosporins, and corticosteroids during the implantation surgery, which were 
discontinued over the same time period that the AEDs were tapered. β-lactam antibiotics, 
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which include cephalosporins, have been reported to upregulate glutamate transporters, 
protect neurons from glutamatergic excitotoxicity, and prevent seizures (Rothstein, Patel 
et al. 2005; Tanaka 2005). Glucocorticoids acutely raise ECF glutamate concentrations in 
the rat hippocampus (242, 243) and have longer-term effects that involve regulation of 
glutamate transporters (244) and glutamine synthetase (245). It is unlikely that these non-
AED medications would have affected the neurochemical comparisons between different 
sites in the single basal analysis, because many patients were on the same antibiotics and 
steroids, but they may have confounded the taper results. Glutamine levels are related to 
blood levels of ammonia, which can be influenced by dietary protein and medications 
such as valproate (165), and this was not examined. Finally, magnetic spectroscopy 
studies (246) and unpublished microdialysis data from our lab indicate that GABA levels 
differ between men and women and fluctuate throughout the menstrual cycle. The gender 
effect on GABA and other neurotransmitters will be examined in a subsequent work.  
 
IV. Conclusions 
 This is a two-part study on the extracellular basal levels of glutamate, glutamine, 
and GABA in subjects with medically-refractory epilepsy initially on their full AED 
doses and then, within a smaller subset, after AED taper. Consisting of 89 subjects, this 
report constitutes the largest microdialysis study, to our knowledge, on basal levels of 
these neurochemicals in patients with medication-refractory epilepsy. This is also the first 
microdialysis study to examine basal GABA levels in both the hippocampus and cortex 
and to examine the neurochemical substrates of seizure propagation sites, lesions, and 
patients with non-localizable epilepsy.  
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Basal glutamate was elevated in epileptogenic and seizure propagation sites 
compared to non-epileptic sites in both the hippocampus and cortex. Glutamate was also 
elevated within lesions and in the cortex of patients with non-localized seizure onset.  In 
the hippocampus and cortex, GABA was significantly elevated in epileptogenic and 
propagated compared to non-epileptic sites, as well as in lesions. There were no 
significant differences in glutamine within the cortex or hippocampus. Since glutamine 
was unchanged, the glutamine/glutamate and glutamine/GABA ratios were lower outside 
of the non-epileptic sites, which could suggest differences in glutamine-glutamate and 
glutamine-GABA cycling. There was no difference between the hippocampus and cortex 
with regard to concentrations of glutamate, glutamine, and GABA. When data from the 
cortex and hippocampus were combined, propagated sites were shown to have higher 
glutamate and GABA than sites of seizure onset, which suggests that neurochemical 
abnormalities may extend beyond and be more prominent in brain regions outside of 
seizure onset sites. 
The second part of this study examined the effects of antiepileptic drug 
withdrawal on levels of glutamate, glutamine, and GABA to ascertain if these 
concentrations were influenced by AEDs. There was a trend toward glutamate decrease 
in non-localized sites. Glutamine decreased significantly in lesion sites following taper, 
and GABA decreased significantly in non-localized sites. When sites were considered 
altogether, there were significant decreases in glutamine and GABA with taper. 
The findings in the single basal component of this study suggest that increased 
extracellular glutamate and GABA extend far beyond the epileptogenic zone, which is 
consistent with findings on structural and metabolic imaging. Glutamate and GABA are 
84  
also elevated in lesions. The medication taper component of this study suggests that 
antiepileptic drugs may reduce seizure frequency by increasing extracellular GABA 
throughout the brain, although their effect on extracellular glutamate is minimal. The 
inability of AEDs to suppress extracellular glutamate to normal levels may be related to 
the medication resistance of epilepsy in these subjects. These results suggest that 
modulation of extracellular glutamate, both in seizure onset and propagation regions, 
should be examined for future antiepileptic pharmacotherapy.  
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